The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (5th Edition) 2020-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    November 2020

  • Pages
    991

  • View Count
    30019

Example Insights

Global-T-Cell-Therapy-Market-Context Global-T-Cell-Therapy-Market-Example-Highlight Global-T-Cell-Therapy-Market-Pipeline Global-T-Cell-Therapy-Market-industry-and-non-industry-players
Global-T-Cell-Therapy-Market-different-stages Global-T-Cell-Therapy-Market-Popular-Targets Global-T-Cell-Therapy-Market-Clinical-Trials Global-T-Cell-Therapy-Market-Mapping-Key-Opinion-Leaders
Global-T-Cell-Therapy-Market-Case-Study Global-T-Cell-Therapy-Market-List-of-Cell-Therapy-Manufacturers Global-T-Cell-Therapy-Market-Partnerships-and-Collaborations Global-T-Cell-Therapy-Market-Funding-and-Investments
Global-T-Cell-Therapy-Market-T-Cell-Immunotherapies Global-T-Cell-Therapy-Market-Distribution-by-Indications Global-T-Cell-Therapy-Market-Distribution-by-Geography Global-T-Cell-Therapy-Market-Promotional-Strategies

 

Overview

According to the World Health Organization (WHO), cancer is considered to be among the second leading causes of mortality worldwide, accounting for an estimated 10 million deaths annually. In fact, the global cancer burden is anticipated to increase by 70% in the next 20 years, exerting tremendous physical, emotional and financial strain on individuals, families, communities and health systems.  Although efforts are being made to develop safe and effective drugs for the treatment of different types of cancer, there is still a pressing need for more specific and potent drugs / therapies to combat this complex, life threatening clinical condition. Amidst the current initiatives to develop more targeted anti-cancer therapies, T-cell therapies (specifically CAR-T, TCR and TIL therapies) have emerged as a promising option owing to their capability to eradicate tumor cells from the body with minimal treatment-related side effects. These adoptive T-cell therapies (ACT) are based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. A number of chimeric antigen receptor T-cell (CAR-T) therapies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences) and TECARTUS™ (Gilead Sciences), have already been approved in the recent years validating the potential of such ACTs in cancer treatment. In addition to the industry stakeholders, more than 300 academic and research institutes, till date, have made significant contributions to this field, mostly by convening the initial research on potential therapy candidates. Prominent scientists, acting as key opinion leaders, are leading the clinical development efforts of more than 975 T-cell therapy candidates for the treatment of various oncological and non-oncological disorders. Several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. 

It is also worth highlighting that capital investments worth over USD 17 billion have been made by various private and public sector investors during the last five years to fund the product development activity. In addition, there have been close to 350 recently reported instances of collaborations between industry / academic stakeholders to advance the development of various pipeline candidates. The ongoing research activity in this field has led to the discovery of several disease-specific targets, such as CD19, BCMA, CD22, CD20 and meso. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the T-cell immunotherapies market is poised for success in the long-run as multiple product candidates are expected to be approved over the coming decade.

Scope of the Report

The “Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (5th Edition) by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, Non-Hodgkin’s Lymphoma, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma, Sarcoma, Chronic Lymphocytic Leukemia, Ovarian Cancer, Esophageal Cancer, Colorectal Cancer, Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia and Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Global Forecast 2020-2030” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of T-cell immunotherapies with respect to type of product (CAR-T, TCR and TIL), type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved), therapeutic area (hematological cancer, solid tumor and others), target therapeutic indication (non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma, brain cancer, acute myeloid leukemia, melanoma, lung cancer, ovarian cancer, liver cancer, pancreatic cancer, chronic lymphocytic leukemia, stomach cancer, breast cancer, sarcoma, mantle cell lymphoma, mesothelioma, colorectal cancer, bladder cancer and others), key target antigen (CD19, BCMA, CD22, CD20, Meso, GD2, CD38, CD123, CD30, HER2, GPC3, CD33 and CD13), source of T-cells (autologous / allogeneic), route of administration (intravenous, intratumor, intraperitoneal, intrapleural, intraventricular and others), dose frequency (single dose, multiple dose and split dose), patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates) and an insightful logo landscape, highlighting product developers in North America, Europe and the Asia Pacific.
  • Detailed profiles of marketed and mid- to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
  • An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector (lentivirus, retrovirus, mRNA and other vectors) and type of co-stimulatory domain used.
  • An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical locations of eminent scientists / researchers involved in the development of T-cell therapies.
  • An analysis of the various CAR-T cell therapy focused clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend of initiation of such studies and distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies, especially in China.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity (in terms of revenue generation potential from therapy sales) across oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
  • An analysis of the partnerships that have been established in the recent past, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of the investments that have been made into companies that have proprietary T-cell based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs, including a detailed analysis of approved / pipeline products, featuring information on current phase of development, target therapeutic area(s), type of T-cells used and source of T-cells.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
  • An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, highlighting the yearly trend of tweets, most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell immunotherapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2020-2030. The report also includes likely sales forecasts of T-cell immunotherapies that have been already commercialized or are in the late stages of development. Additionally, it features market size projections for the overall T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others) and [D] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Peter Ho (Director, Process Development, Iovance Biotherapeutics)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
  • Patrick Dougherty (SVP, Strategy, Planning and Operations, Windmil Therapeutics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the prevalent R&D trends related to T-cell immunotherapies?
  • What are the key therapeutic areas for which T-cell immunotherapies are being / have been developed?
  • What are the challenges faced by stakeholders engaged in this domain?
  • Who are the leading industry and non-industry players in this market?
  • In which geographies an extensive research on T-cell immunotherapy is being conducted?
  • Who are the key investors in this domain? 
  • Who are the key opinion leaders / experts in this upcoming field of therapeutics?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • What kind of contract manufacturing support is available for T-cell therapies, across different regions?
  • What kind of promotional strategies are likely to be adopted for T-cell therapies that are approved and commercialized in future?
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments? 

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the T-cell immunotherapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapies. Moreover, it features detailed sections on the three major types of T-cell immunotherapies, namely CAR-T, TCR and TIL-based therapies, which are the main focus of the study.

Chapter 4 provides insights on the popularity of T-cell immunotherapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2019, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter highlights the most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.

Chapter 5 includes detailed assessment on more than 975 T-cell immunotherapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the type of product (CAR-T, TCR and TIL), type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved), therapeutic area (hematological cancer, solid tumor and others), target therapeutic indication (non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma, brain cancer, acute myeloid leukemia, melanoma, lung cancer, ovarian cancer, liver cancer, pancreatic cancer, chronic lymphocytic leukemia, stomach cancer, breast cancer, sarcoma, mantle cell lymphoma, mesothelioma, colorectal cancer, bladder cancer and others), key target antigen (CD19, BCMA, CD22, CD20, Meso, GD2, CD38, CD123, CD30, HER2, GPC3, CD33 and CD13), source of T-cells (autologous / allogeneic), route of administration (intravenous, intratumor, intraperitoneal, intrapleural, intraventricular and others), dose frequency (single dose, multiple dose and split dose), patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates) and an insightful logo landscape, highlighting product developers in North America, Europe and the Asia Pacific. 

Chapter 6 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T and TCR therapies in hematological cancer and solid tumor space. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapies (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector (lentivirus, retrovirus, mRNA and other vectors) and type of co-stimulatory domain used.

Chapter 7 presents an analysis of the CAR-T clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend and the distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies market in China.

Chapter 8 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 9 provides detailed profiles of the mid to late stage TCR therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 10 provides detailed profiles of the mid to late stage TIL therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 11 identifies the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the T-cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 12 provides a list of technology platforms that are either available in the market or under designed for the development of T-cell immunotherapies. A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.

Chapter 13 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 14 provides details on the various investments and grants that have been awarded to players focused on the development of T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 15 features details of other novel T-cell based therapies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. It presents a detailed analysis of the approved / clinical products in this domain, including information on current phase of development, target therapeutic areas, type of cells, and source of T-cells. Additionally, we have provided a brief overview of the upcoming therapies, along with details on their mechanisms of action.

Chapter 16 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 17 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 18 features an elaborate discussion on the future commercial opportunity offered by T-cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others) and [D] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world).

Chapter 19 highlights the key promotional strategies that are being implemented by the developers of the marketed products, KYMRIAH® and YESCARTA®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 20 includes brief company profiles of the leading players in the T-cell immunotherapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 21 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 22 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Chief Executive Officer, Cell Therapies), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Miguel Forte (Chief Operating Officer, TxCell), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Director, Process Development, Iovance Biotherapeutics), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital), Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) and Patrick Dougherty (SVP, Strategy, Planning and Operations, Windmil Therapeutics)

Chapter 23 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 24 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution

3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods

3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
3.7.1. History of Development
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane (TM) Domain
3.7.2.3. Endodomain
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration of CAR-T Cell Therapies
3.7.6. Case Study: CD19 CAR-T Cell Therapies
3.7.6.1. Other Important Biological Targets for CAR Development
3.7.7. Challenges Associated with CAR-T Cell Therapies
3.7.7.1. Competitive Risks
3.7.7.2. Clinical Risks
3.7.7.3. Regulatory Risks
3.7.7.4. Commercial Risks

3.8. T-Cell Receptor (TCR)-based Cell Therapy
3.8.1. History of Development
3.8.2. Anatomical Layout of TCR
3.8.3. Development of TCR for Therapy
3.8.4. Differences between CAR-T and TCR-based Therapies

3.9. Tumor Infiltrating Lymphocyte (TIL)-based Therapy
3.9.1. History of Development
3.9.2. Development of TILs for Therapy
3.10. Key Challenges and Roadblocks

3.11. Concluding Remarks

4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. T-Cell Immunotherapies: Trends on Twitter
4.2.1. Historical Trend in Volume of Tweets
4.2.2. Trending Words / Phrases on Twitter
4.2.3. Most Popular Drugs on Twitter
4.2.4. Most Prolific Authors on Twitter
4.2.5. Most Popular Indications and Target Antigens

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. T-Cell Immunotherapies: Overall Market Overview
5.2.1. Analysis by Type of Product
5.3. CAR-T Cell Therapies: Overall Market Overview
5.3.1. Analysis by Type of Developer
5.3.2. Analysis by Phase of Development
5.3.3. Analysis by Therapeutic Area
5.3.4. Analysis by Popular Target Indications
5.3.5. Analysis by Popular Target Antigens
5.3.6. Analysis by Source of T-Cells
5.3.7. Analysis by Route of Administration
5.3.8. Analysis by Dose Frequency
5.3.9. Analysis by Patient Segment
5.3.10. Analysis by Type of Therapy
5.3.11. Key Industry Players: Analysis by Number of CAR-T Cell Therapies in Development
5.3.12. Key Non-Industry Players: Analysis by Number of CAR-T Cell Therapies in Development

5.4. TCR-based Therapies: Overall Market Overview
5.4.1. Analysis by Type of Developer
5.4.2. Analysis by Phase of Development
5.4.3. Analysis by Therapeutic Area
5.4.4. Analysis by Popular Target Indications
5.4.5. Analysis by Popular Target Antigens
5.4.6. Analysis by Source of T-Cells
5.4.7. Analysis by Route of Administration
5.4.8. Analysis by Dose Frequency
5.4.9. Analysis by Patient Segment
5.4.10. Analysis by Type of Therapy
5.4.11. Key Industry Players: Analysis by Number of TCR-based Therapies in Development
5.4.12. Key Non-Industry Players: Analysis by Number of TCR-based Therapies in Development

5.5. TIL-based Therapies: Overall Market Overview
5.5.1. Analysis by Type of Developer
5.5.2. Analysis by Phase of Development
5.5.3. Analysis by Therapeutic Area
5.5.4. Analysis by Popular Target Indications
5.5.5. Analysis by Source of T-Cells
5.5.6. Analysis by Route of Administration
5.5.7. Analysis by Dose Frequency
5.5.8. Analysis by Patient Segment
5.5.9. Analysis by Type of Therapy
5.5.10. Key Industry Players: Analysis by Number of TIL-based Therapies in Development
5.5.11. Key Non-Industry Players: Analysis by Number of TIL-based Therapies in Development

6. KEY INSIGHTS
6.1. Chapter Overview
6.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigens
6.2.1. Popular Targets Related to Haematological Malignancies
6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Therapies
6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Therapies
6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Therapies
6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Therapies

6.2.2. Solid Tumors: Popular Targets
6.2.2.1. Competitive Landscape of Meso CAR-T Cell Therapies
6.2.2.2. Clinical Trial Results of Prominent Meso CAR-T Cell Therapies
6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Therapies
6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Therapies

6.3. T-Cell Immunotherapies: Key Opinion Leaders
6.3.1. CAR-T Cell Therapies: Key Opinion Leaders
6.3.2. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders
6.3.3. TCR-based Therapies: Key Opinion Leaders
6.3.4. TCR-based Therapies: Most Prominent Key Opinion Leaders
6.3.5. TIL-based therapies: Key Opinion Leaders
6.3.6. TIL-based Therapies: Most Prominent Key Opinion Leaders

6.4. T-Cell Immunotherapies: CAR Construct Analysis
6.4.1. Analysis by Generation of CAR
6.4.2. Analysis by Type of scFv Antibody
6.4.3. Analysis by Type of Vector
6.4.4. Analysis by Type of Co-Stimulatory Domain(s)

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Clinical Trial Analysis
7.2.1. Methodology
7.2.2. Analysis by Trial Registration Year
7.2.3. Geographical Analysis by Number of Registered Trials
7.2.4. Case Study: CAR-T Cell Therapy Market in China
7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China

8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. KYMRIAH® / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. Current Development Status
8.2.3. Key Clinical Trial Results
8.2.4. Dosage Regimen, Price and Manufacturing

8.3. YESCARTA® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing

8.4. Tecartus / Brexucabtagene Autoleucel (Kite Pharma)
8.4.1. Therapy Overview
8.4.2. Current Development Status
8.4.3. Key Clinical Trial Results
8.4.4. Dosage Regimen, Price and Manufacturing

8.5. JCAR (Juno Therapeutics)
8.5.1. Therapy Overview
8.5.2. Current Development Status
8.5.3. Key Clinical Results
8.5.3.1. JCAR014
8.5.3.2. JCAR017
8.5.3.3. JCAR018
8.5.3.4. JCARH125
8.5.4. Dosage Regimen and Manufacturing

8.6. Idecabtagene Vicleucel / bb2121 (bluebird bio / Celgene)
8.6.1. Therapy Overview
8.6.2. Current Development Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing

8.7. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen Biotech)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing

8.8. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
8.8.1. Therapy Overview
8.8.2. Current Development Status
8.8.3. Key Clinical Trial Results
8.8.4. Dosage Regimen and Manufacturing

8.9. Dual Targeting CAR-T Cell therapies (Autolus)
8.9.1. Therapy Overview
8.9.2. Current Development Status
8.9.3. Key Clinical Trial Results
8.9.3.1. AUTO2
8.9.3.2. AUTO3
8.9.3.3. AUTO4
8.9.4. Dosage Regimen and Manufacturing

8.10. CAR-T Cell Therapies (Sinobioway Cell Therapy)
8.10.1. Therapy Overview
8.10.2. Current Development Status
8.10.3. Dosage Regimen and Manufacturing

9. TCR-BASED THERAPY PROFILES
9.1. Chapter Overview
9.2. SPEAR T-Cells (Adaptimmune / GlaxoSmithKline)
9.2.1. Therapy Overview
9.2.1.1. SPEAR T-Cells Technology Platform
9.2.1.2. NY-ESO SPEAR T-Cell
9.2.1.3. Mage-A10 T-Cell Therapy
9.2.1.4. AFP T-Cell Therapy
9.2.1.5. Mage-A4 T-Cell Therapy
9.2.2. Current Development Status
9.2.3. Key Clinical Trial Results
9.2.4. Dosage Regimen and Manufacturing

9.3. IMCgp100 (Immunocore)
9.3.1. Therapy Overview
9.3.2. Current Development Status
9.3.3. Key Clinical Trial Results
9.3.4. Dosage Regimen and Manufacturing

9.4. ALT-801 (Altor BioScience)
9.4.1. Therapy Overview
9.4.2. Current Development Status
9.4.3. Key Clinical Trial Results
9.4.4. Dosage Regimen
9.4.5. Patent Portfolio

9.5. JTCR016 (Juno Therapeutics)
9.5.1. Therapy Overview
9.5.2. Current Development Status
9.5.3. Key Clinical Trial Results
9.5.4. Dosage Regimen and Manufacturing

9.6. CMD-602 / WT1 TCR Therapy (Cell Medica)
9.6.1. Therapy Overview
9.6.1.1. History of Development
9.6.2. Current Development Status
9.6.3. Key Clinical Trial Results
9.6.4. Dosage Regimen and Manufacturing

9.7. TBI-1301 (Takara Bio)
9.7.1. Therapy Overview
9.7.2. Current Development Status
9.7.3. Key Clinical Trial Results
9.7.4. Dosage Regimen and Manufacturing

9.8. MDG1011 (Medigene)
9.8.1. Therapy Overview
9.8.2. Current Development Status
9.8.3. Key Clinical Trial Results
9.8.4. Dosage Regimen and Manufacturing

10. TIL-BASED THERAPY PROFILES
10.1. Chapter Overview
10.2. Autologous TIL Therapies (Iovance Biotherapeutics)
10.2.1. Therapy Overview
10.2.2. Current Development Status
10.2.2.1. LN-144
10.2.2.2. LN-145
10.2.3. Key Clinical Trial Results
10.2.4. Dosage Regimen and Manufacturing
10.2.5. Patent Portfolio

10.3. TIL (Nantes University Hospital)
10.3.1. Therapy Overview
10.3.2. Current Development Status
10.3.3. Key Clinical Trial Results
10.3.4. Dosage Regimen and Manufacturing

10.4. TIL (Netherlands Cancer Institute)
10.4.1. Therapy Overview
10.4.2. Current Development Status
10.4.3. Key Clinical Trial Results
10.4.4. Dosage Regimen and Manufacturing

11. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES
11.1. Chapter Overview
11.2. Hematological Malignancies
11.2.1. Leukemia and Lymphoma
11.2.1.1. Leukemia: Introduction and Epidemiology
11.2.1.1.1. Acute Myeloid Leukemia (AML)
11.2.1.1.2. Chronic Myeloid Leukemia (CML)
11.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
11.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
11.2.1.2. Lymphoma: Introduction and Epidemiology
11.2.1.3. Current Treatment Landscape
11.2.1.3.1. Targeted Therapies
11.2.1.4. T-Cell Immunotherapy and Affiliated Research Landscape
11.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma
11.2.1.4.2. TCR-based Therapies and Leukemia / Lymphoma
11.2.1.4.3. TIL-based Therapies and Leukemia

11.2.2. Multiple Myeloma
11.2.2.1. Introduction and Epidemiology
11.2.2.2. Current Treatment Landscape
11.2.2.3. T-Cell Immunotherapy and Affiliated Research Landscape

11.3. Solid Tumors
11.3.1. Metastatic Melanoma
11.3.1.1. Introduction and Epidemiology
11.3.1.2. Current Treatment Landscape
11.3.1.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.1.3.1. CAR-T Cell Therapies and Metastatic Melanoma
11.3.1.3.2. TCR-based Therapies and Metastatic Melanoma
11.3.1.3.3. TIL-based Therapies and Metastatic Melanoma

11.3.2. Lung Cancer
11.3.2.1. Introduction and Epidemiology
11.3.2.2. Current Treatment Landscape
11.3.2.3. T-Cell Immunotherapy and Affiliated Research Landscape

11.3.3. Pancreatic Cancer
11.3.3.1. Introduction and Epidemiology
11.3.3.2. Current Treatment Landscape
11.3.3.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.3.3.1. CAR-T Cell Therapies and Pancreatic Cancer
11.3.3.3.2. TCR-based Therapies and Pancreatic Cancer
11.3.3.3.3. TIL-based Therapies and Pancreatic Cancer

11.3.4. Liver Cancer
11.3.4.1. Current Treatment Landscape
11.3.4.2. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.4.2.1. CAR-T Cell Therapies and Liver Cancer
11.3.4.2.2. TCR-based Therapies and Liver Cancer
11.3.4.2.3. TIL-based Therapies and Liver Cancer

11.3.5. Breast Cancer
11.3.5.1. Introduction and Epidemiology
11.3.5.2. Current Treatment Landscape
11.3.5.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.5.3.1. CAR-T Cell Therapies and Breast Cancer
11.3.5.3.2. TCR-based Therapies and Breast Cancer
11.3.5.3.3. TIL-based Therapies and Breast Cancer

11.3.6. Ovarian Cancer
11.3.6.1. Introduction and Epidemiology
11.3.6.2. Current Treatment Landscape
11.3.6.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.6.3.1. CAR-T Cell Therapies and Ovarian Cancer
11.3.6.3.2. TCR-based Therapies and Ovarian Cancer
11.3.6.3.3. TIL-based Therapies and Ovarian Cancer

11.3.7. Bladder Cancer
11.3.7.1. Introduction and Epidemiology
11.3.7.2. Current Treatment Landscape
11.3.7.3. T-Cell Immunotherapy and Affiliated Research Landscape

11.3.8. Kidney Cancer
11.3.8.1. Introduction and Epidemiology
11.3.8.2. Current Treatment Landscape
11.3.8.3. T-Cell Immunotherapy and Affiliated Research Landscape

12. EMERGING TECHNOLOGIES
12.1. Chapter Overview
12.2. Genome Editing Technologies
12.2.1. Technology Overviews
12.2.2. Applications
12.2.3. Emerging Technology Platforms Used in T-Cell Therapies
12.2.3.1. CRISPR / Cas9 System
12.2.3.1.1. Key Components and Function
12.2.3.1.2. Mechanism of Action
12.2.3.1.3. Targeting Efficiency and Challenges
12.2.3.1.4. Next-GEN CRISPR Technology
12.2.3.1.5. Technology Providers
12.2.3.1.5.1. Editas Medicine
12.2.3.1.5.2. Intellia Therapeutics
12.2.3.1.5.3. CRISPR Therapeutics
12.2.3.1.5.4. Beam Therapeutics
12.2.3.1.5.5. Gracell Biotechnologies

12.2.3.2. TALENs
12.2.3.2.1. Key Components and Function
12.2.3.2.2. Mechanism of Action
12.2.3.2.3. Advantages and Challenges
12.2.3.2.4. Technology Providers
12.2.3.2.4.1. Cellectis
12.2.3.2.4.2. Editas Medicine

12.2.3.3. megaTAL
12.2.3.3.1. Technology Providers
12.2.3.3.1.1. bluebird bio

12.2.3.4. Zinc Finger Nuclease
12.2.3.4.1. Technology Providers
12.2.3.4.1.1. Sangamo Therapeutics
12.2.4. Competitive Analysis: Gene Editing Platforms

12.3. Designing T-Cell Therapies with Improved Characteristics
12.3.1. Technologies for Targeting Multiple Cancers
12.3.1.1. Antibody Coupled T-Cell Receptor
12.3.1.1.1. Unum Therapeutics
12.3.1.2. NKR-T Platform
12.3.1.2.1. Celyad
12.3.1.2.2. Glycostem

12.3.2. Technologies for Improved Safety
12.3.2.1. Armored CAR and EGFRt Technology
12.3.2.1.1. Juno Therapeutics
12.3.2.2. RheoSwitch Therapeutic System
12.3.2.2.1. Intrexon
12.3.2.1. Inducible Caspase 9 Safety Switch
12.3.2.1.1. Bellicum Pharmaceuticals
12.3.2.1.1.1. CaspaCIDe Technology
12.3.2.1.1.2. CIDeCAR Technology
12.3.2.1.1.3. GoCAR-T Technology
12.3.2.2. On-Off Switch, Multiple Companies
12.3.2.2.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
12.3.2.2.2. On-Off Switch (Theravectys)
12.3.2.3. Other Technologies to Improve CAR-T Safety

12.3.3. Allogeneic Technologies
12.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
12.3.3.2. Allogeneic Platform (Celyad)
12.3.3.3. Allogeneic Platform (Cellectis)

13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. T-Cell Immunotherapies Market: Partnerships and Collaborations
13.3.1. Analysis by Year of Partnerships
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Type of Partnership and Type of Product
13.3.4. Analysis by Type of Industry and Type of Product
13.3.5. Analysis by Individual Products
13.3.6. Most Active Industry Players: Analysis by Number of Partnerships
13.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
13.3.8. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
13.3.9. Regional Analysis
13.3.10. Intercontinental and Intracontinental Agreements

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
14.3.1. Analysis by Number of Funding Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Amount Invested across Different Types of Therapies
14.3.5. Most Active Players: Analysis by Number of Instances
14.3.6. Analysis by Amount Invested by Different Type of Investors
14.3.7. Most Active Investors: Analysis by Number of Instances
14.3.8. Regional Analysis by Amount Invested

15. OTHER T-CELL IMMUNOTHERAPIES
15.1. Chapter Overview
15.2. Other T-Cell Immunotherapies
15.2.1. Analysis by Phase of Development
15.2.2. Analysis by Target Therapeutic Area
15.2.3. Analysis by Types of Cells
15.2.4. Analysis by Source of T-Cells

15.3. Treg Cell Therapy
15.3.1. Caladrius Biosciences
15.3.2. TRACT Therapeutics
15.3.3. Cellenkos
15.3.4. Other Companies

15.4. T-Cell-based Vaccines
15.4.1. Immunovative Therapies
15.4.2. TVAX Biomedical

15.5. Virus-Driven T-Cell Therapy
15.5.1. Atara Biotherapeutics
15.5.2. bluebird bio
15.5.3. Cell Medica
15.5.4. Eutilex
15.5.5. Tessa Therapeutics
15.5.6. ViGenCell

15.6. Fucosylated T-Cell Therapy
15.6.1. Targazyme

15.7. PD-1 Knockout Engineered T-Cell Therapy
15.7.1. Chengdu MedGenCell
15.7.2. Anhui Kedgene Biotechnology
15.8. TAC-T Cell Therapy
15.8.1. Triumvira Immunologics

15.9. Gama Delta T-Cell Therapy
15.9.1. GammaCell Bio-Technologies
15.9.2. TC Biopharm

16. CASE STUDY: CELL THERAPY MANUFACTURING
16.1. Chapter Overview
16.2. Overview of Cell Therapy Manufacturing
16.3. Cell Therapy Manufacturing Models
16.3.1. Centralized Manufacturing Model
16.3.2. Decentralized Manufacturing Model
16.4. Scalability of Cell Therapy Manufacturing Processes
16.4.1. Scale-Up
16.4.2. Scale-Out
16.5. Types of Cell Therapy Manufacturers
16.6. Key Challenges Related to Manufacturing Cell Therapies
16.7. Important Factors for Cell Therapy Manufacturing
16.7.1. Characterization
16.7.2. Cost of Goods
16.8. Automation of Cell Therapy Manufacturing Processes
16.9. Cell Therapy Manufacturing Supply Chain
16.10. Companies with In-House Capabilities
16.11. Contract Manufacturers
16.12. Regulatory Landscape

17. COST PRICE ANALYSIS
17.1. Chapter Overview
17.2. Factors Contributing to the High Price of Cell / Gene Therapies
17.3. Pricing Models for T-Cell Immunotherapies
17.3.1. Based on Associated Costs
17.3.2. Based on Availability of Competing Products
17.3.3. Based on Patient Segment
17.3.4. Based on the Opinions of Industry Experts
17.4. Reimbursement-related Considerations For T-Cell Immunotherapies
17.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

18. MARKET SIZING AND OPPORTUNITY ANALYSIS
18.1. Chapter Overview
18.2. Scope and Limitations
18.3. Key Assumptions and Forecast Methodology
18.4. Overall T-Cell Immunotherapy Market, 2019-2030
18.4.1. T-Cell Immunotherapy Market: Distribution by Type of Therapy
18.4.2. T-Cell Immunotherapy Market: Distribution by Target Indications
18.4.3. T-Cell Immunotherapy Market: Distribution by Target Antigen
18.4.4. T-Cell Immunotherapy Market: Distribution by Key Players
18.4.5. T-Cell Immunotherapy Market: Distribution by Geography
18.5. T-Cell Immunotherapy Market: Value Creation Analysis

18.6. Overall CAR-T Cell Therapies Market, 2019-2030
18.6.1. CAR-T Cell Therapies Market: Distribution by Target Indication
18.6.2. CAR-T Cell Therapies Market: Distribution by Target Antigen
18.6.3. CAR-T Cell Therapies Market: Distribution by Key Players
18.6.4. CAR-T Cell Therapies Market: Distribution by Geography
18.6.5. Product Wise Sales Forecasts
18.6.5.1. KYMRIAH® (Novartis)
18.6.5.1.1. Target Patient Population
18.6.5.1.2. Sales Forecast
18.6.5.1.3. Net Present Value
18.6.5.1.4. Value Creation Analysis

18.6.5.2. YESCARTA® (Gilead Sciences)
18.6.5.2.1. Target Patient Population
18.6.5.2.2. Sales Forecast
18.6.5.2.3. Net Present Value
18.6.5.2.4. Value Creation Analysis

18.6.5.3. Tecartus® / Brexucabtagene Autoleucel (Gilead Sciences)
18.6.5.3.1. Target Patient Population
18.6.5.3.2. Sales Forecast
18.6.5.3.3. Net Present Value
18.6.5.3.4. Value Creation Analysis

18.6.5.4. Idecabtagene Vicleucel / bb2121 (bluebird bio / Celgene)
18.6.5.4.1. Target Patient Population
18.6.5.4.2. Sales Forecast
18.6.5.4.3. Net Present Value
18.6.5.4.4. Value Creation Analysis

18.6.5.5. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
18.6.5.5.1. Target Patient Population
18.6.5.5.2. Sales Forecast
18.6.5.5.3. Net Present Value
18.6.5.5.4. Value Creation Analysis

18.6.5.6. JCAR017 (Juno Therapeutics / Celgene / Wuxi AppTec)
18.6.5.6.1. Target Patient Population
18.6.5.6.2. Sales Forecast
18.6.5.6.3. Net Present Value
18.6.5.6.4. Value Creation Analysis

18.6.5.7. MB-CART19.1 (Miltenyi Biotec)
18.6.5.7.1. Target Patient Population
18.6.5.7.2. Sales Forecast
18.6.5.7.3. Net Present Value
18.6.5.7.4. Value Creation Analysis

18.6.5.8. Descartes-11 (Cartesian Therapeutics)
18.6.5.8.1. Target Patient Population
18.6.5.8.2. Sales Forecast
18.6.5.8.3. Net Present Value
18.6.5.8.4. Value Creation Analysis

18.6.5.9. MB-102 (Mustang Bio)
18.6.5.9.1. Target Patient Population
18.6.5.9.2. Sales Forecast
18.6.5.9.3. Net Present Value
18.6.5.9.4. Value Creation Analysis

18.6.5.10. huCART19 / CTL119 (Novartis)
18.6.5.10.1. Target Patient Population
18.6.5.10.2. Sales Forecast
18.6.5.10.3. Net Present Value
18.6.5.10.4. Value Creation Analysis

18.6.5.11. CD19 CAR-T (Sinobioway Cell Therapy)
18.6.5.11.1. Target Patient Population
18.6.5.11.2. Sales Forecast
18.6.5.11.3. Net Present Value
18.6.5.11.4. Value Creation Analysis

18.6.5.12. AUTO1 (Autolus)
18.6.5.12.1. Target Patient Population
18.6.5.12.2. Sales Forecast
18.6.5.12.3. Net Present Value
18.6.5.12.4. Value Creation Analysis

18.6.5.13. AUTO3 (Autolus)
18.6.5.13.1. Target Patient Population
18.6.5.13.2. Sales Forecast
18.6.5.13.3. Net Present Value
18.6.5.13.4. Value Creation Analysis

18.6.5.14. AUTO4 (Autolus)
18.6.5.14.1. Target Patient Population
18.6.5.14.2. Sales Forecast
18.6.5.14.3. Net Present Value
18.6.5.14.4. Value Creation Analysis

18.6.5.15. GPC3 CAR-T (Shanghai GeneChem)
18.6.5.15.1. Target Patient Population
18.6.5.15.2. Sales Forecast
18.6.5.15.3. Net Present Value
18.6.5.15.4. Value Creation Analysis

18.6.5.16. BCMA CAR-T (The Pregene ShenZhen Biotechnology)
18.6.5.16.1. Target Patient Population
18.6.5.16.2. Sales Forecast
18.6.5.16.3. Net Present Value
18.6.5.16.4. Value Creation Analysis

18.6.5.17. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
18.6.5.17.1. Target Patient Population
18.6.5.17.2. Sales Forecast
18.6.5.17.3. Net Present Value
18.6.5.17.4. Value Creation Analysis

18.6.5.18. CD19 CAR-T (Shanghai Bioray Laboratory)
18.6.5.18.1. Target Patient Population
18.6.5.18.2. Sales Forecast
18.6.5.18.3. Net Present Value
18.6.5.18.4. Value Creation Analysis

18.6.5.19. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
18.6.5.19.1. Target Patient Population
18.6.5.19.2. Sales Forecast
18.6.5.19.3. Net Present Value
18.6.5.19.4. Value Creation Analysis

18.6.5.20. PCAR-019 (PersonGen BioTherapeutics)
18.6.5.20.1. Target Patient Population
18.6.5.20.2. Sales Forecast
18.6.5.20.3. Net Present Value
18.6.5.20.4. Value Creation Analysis

18.6.5.21. TBI-1501 (Takara Bio)
18.6.5.21.1. Target Patient Population
18.6.5.21.2. Sales Forecast
18.6.5.21.3. Net Present Value
18.6.5.21.4. Value Creation Analysis

18.6.5.22. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
18.6.5.22.1. Target Population
18.6.5.22.2. Sales Forecast
18.6.5.22.3. Net Present Value
18.6.5.22.4. Value Creation Analysis

18.6.5.23. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
18.6.5.23.1. Target Patient Population
18.6.5.23.2. Sales Forecast
18.6.5.23.3. Net Present Value
18.6.5.23.4. Value Creation Analysis
18.6.5.24. BinD19 (Shenzhen BinDeBio)
18.6.5.24.1. Target Patient Population
18.6.5.24.2. Sales Forecast
18.6.5.24.3. Net Present Value
18.6.5.24.4. Value Creation Analysis

18.6.5.25. CARCIK-CD19 (Formula Pharmaceuticals)
18.6.5.25.1. Target Patient Population
18.6.5.25.2. Sales Forecast
18.6.5.25.3. Net Present Value
18.6.5.25.4. Value Creation Analysis

18.6.5.26. EGFR CART Cell Therapy (The Beijing Pregene Science and Technology)
18.6.5.26.1. Target Patient Population
18.6.5.26.2. Sales Forecast
18.6.5.26.3. Net Present Value
18.6.5.26.4. Value Creation Analysis

18.6.5.27. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
18.6.5.27.1. Target Patient Population
18.6.5.27.2. Sales Forecast
18.6.5.27.3. Net Present Value
18.6.5.27.4. Value Creation Analysis

18.6.5.28. PBCAR269A (Precision BioSciences)
18.6.5.28.1. Target Patient Population
18.6.5.28.2. Sales Forecast
18.6.5.28.3. Net Present Value
18.6.5.28.4. Value Creation Analysis

18.6.5.29. CD123 CAR-T cells (Chongqing Precision Biotech)
18.6.5.29.1. Target Patient Population
18.6.5.29.2. Sales Forecast
18.6.5.29.3. Net Present Value
18.6.5.29.4. Value Creation Analysis
18.6.5.30. BCMA CAR-T (Chongqing Precision Biotech)
18.6.5.30.1. Target Patient Population
18.6.5.30.2. Sales Forecast
18.6.5.30.3. Net Present Value
18.6.5.30.4. Value Creation Analysis

18.6.5.31. CEA CAR-T cells (Chongqing Precision Biotech)
18.6.5.31.1. Target Patient Population
18.6.5.31.2. Sales Forecast
18.6.5.31.3. Net Present Value
18.6.5.31.4. Value Creation Analysis

18.6.5.32. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
18.6.5.32.1. Target Patient Population
18.6.5.32.2. Sales Forecast
18.6.5.32.3. Net Present Value
18.6.5.32.4. Value Creation Analysis

18.6.5.33. P-BCMA-101 (Poseida Therapeutics)
18.6.5.33.1. Target Patient Population
18.6.5.33.2. Sales Forecast
18.6.5.33.3. Net Present Value
18.6.5.33.4. Value Creation Analysis

18.6.5.34. CD19 CAR-T (iCarTAB BioMed)
18.6.5.34.1. Target Patient Population
18.6.5.34.2. Sales Forecast
18.6.5.34.3. Net Present Value
18.6.5.34.4. Value Creation Analysis

18.6.5.35. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
18.6.5.35.1. Target Patient Population
18.6.5.35.2. Sales Forecast
18.6.5.35.3. Net Present Value
18.6.5.35.4. Value Creation Analysis
18.6.5.36. BPX-601 (Bellicum Pharmaceuticals)
18.6.5.36.1. Target Patient Population
18.6.5.36.2. Sales Forecast
18.6.5.36.3. Net Present Value
18.6.5.36.4. Value Creation Analysis

18.6.5.37. MUC1 CAR-T (PersonGen BioTherapeutics (Suzhou))
18.6.5.37.1. Target Patient Population
18.6.5.37.2. Sales Forecast
18.6.5.37.3. Net Present Value
18.6.5.37.4. Value Creation Analysis

18.7. Overall TCR-based Therapies Market
18.7.1. TCR-Based Therapies Market: Distribution by Target Indication
18.7.2. TCR-Based Therapies Market: Distribution by Target Antigen
18.7.3. TCR-Based Therapies Market: Distribution by Key Players
18.7.4. TCR-Based Therapies Market: Distribution by Geography

18.7.5. Product Wise Sales Forecasts
18.7.5.1. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck)
18.7.5.1.1. Target Patient Population
18.7.5.1.2. Sales Forecast
18.7.5.1.3. Net Present Value
18.7.5.1.4. Value Creation Analysis

18.7.5.2. IMCgp100 (Immunocore)
18.7.5.2.1. Target Patient Population
18.7.5.2.2. Sales Forecast
18.7.5.2.3. Net Present Value
18.7.5.2.4. Value Creation Analysis

18.7.5.3. ADP-A2M4 (Adaptimmune Therapeutics)
18.7.5.3.1. Target Patient Population
18.7.5.3.2. Sales Forecast
18.7.5.3.3. Net Present Value
18.7.5.3.4. Value Creation Analysis

18.7.5.4. TBI-1301 (Takara Bio)
18.7.5.4.1. Target Patient Population
18.7.5.4.2. Sales Forecast
18.7.5.4.3. Net Present Value
18.7.5.4.4. Value Creation Analysis

18.7.5.5. ALT 801 (Altor BioScience)
18.7.5.5.1. Target Patient Population
18.7.5.5.2. Sales Forecast
18.7.5.5.3. Net Present Value
18.7.5.5.4. Value Creation Analysis

18.7.5.6. JTCR016 (Juno Therapeutics)
18.7.5.6.1. Target Patient Population
18.7.5.6.2. Sales Forecast
18.7.5.6.3. Net Present Value
18.7.5.6.4. Value Creation Analysis

18.7.5.7. LioCyx (Lion TCR)
18.7.5.7.1. Target Patient Population
18.7.5.7.2. Sales Forecast
18.7.5.7.3. Net Present Value
18.7.5.7.4. Value Creation Analysis

18.7.5.8. YT-E001 (China Immunotech)
18.7.5.8.1. Target Patient Population
18.7.5.8.2. Sales Forecast
18.7.5.8.3. Net Present Value
18.7.5.8.4. Value Creation Analysis

18.7.5.9. MDG1011 (Medigene)
18.7.5.9.1. Target Patient Population
18.7.5.9.2. Sales Forecast
18.7.5.9.3. Net Present Value
18.7.5.9.4. Value Creation Analysis

18.7.5.10. TC-110 (TCR2 Therapeutics)
18.7.5.10.1. Target Patient Population
18.7.5.10.2. Sales Forecast
18.7.5.10.3. Net Present Value
18.7.5.10.4. Value Creation Analysis

18.7.5.11. LMBP2-specific TCR-T (TCR CURE Biopharma Technology)
18.7.5.11.1. Target Patient Population
18.7.5.11.2. Sales Forecast
18.7.5.11.3. Net Present Value
18.7.5.11.4. Value Creation Analysis

18.8. Overall TIL-Based Therapies Market
18.8.1. TIL-Based Therapies Market: Distribution by Target Indication
18.8.2. TIL-Based Therapies Market: Distribution by Key Players
18.8.3. TIL-Based Therapies Market: Distribution by Geography

18.8.4. Product Wise Sales Forecasts
18.8.4.1. TILs (Nantes University Hospital)
18.8.4.1.1. Target Patient Population
18.8.4.1.2. Sales Forecast
18.8.4.1.3. Net Present Value
18.8.4.1.4. Value Creation Analysis

18.8.4.2. TILs (Netherlands Cancer Institute)
18.8.4.2.1. Target Patient Population
18.8.4.2.2. Sales Forecast
18.8.4.2.3. Net Present Value
18.8.4.2.4. Value Creation Analysis

18.8.4.3. Lifileucel (LN-144) (Iovance Biotherapeutics)
18.8.4.3.1. Target Patient Population
18.8.4.3.2. Sales Forecast
18.8.4.3.3. Net Present Value
18.8.4.3.4. Value Creation Analysis

18.8.4.4. LN-145 (Iovance Biotherapeutics)
18.8.4.4.1. Target Patient Population
18.8.4.4.2. Sales Forecast
18.8.4.4.3. Net Present Value
18.8.4.4.4. Value Creation Analysis

18.8.4.5. LTX-315 and TILs (Lytix Biopharma)
18.8.4.5.1. Target Patient Population
18.8.4.5.2. Sales Forecast
18.8.4.5.3. Net Present Value
18.8.4.5.4. Value Creation Analysis

18.8.4.6 IOV-2001 (Iovance Biotherapeutics)
18.8.4.6.1. Target Patient Population
18.8.4.6.2. Sales Forecast
18.8.4.6.3. Net Present Value
18.8.4.6.4. Value Creation Analysis

18.8.4.7. Allogeneic Donor Lymphocytes (Amgen)
18.8.4.7.1. Target Patient Population
18.8.4.7.2. Sales Forecast
18.8.4.7.3. Net Present Value
18.8.4.7.4. Value Creation Analysis

18.8.4.8. Donor Lymphocyte Infusion (Incyte)
18.8.4.8.1. Target Patient Population
18.8.4.8.2. Sales Forecast
18.8.4.8.3. Net Present Value
18.8.4.8.4. Value Creation Analysis

18.8.4.9. TILs (Bristol-Myers Squibb)
18.8.4.9.1. Target Patient Population
18.8.4.9.2. Sales Forecast
18.8.4.9.3. Net Present Value
18.8.4.9.4. Value Creation Analysis

18.8.4.10. UTIL-01 and CoTIL-01 (Immetacyte)
18.8.4.10.1. Target Patient Population
18.8.4.10.2. Sales Forecast
18.8.4.10.3. Net Present Value
18.8.4.10.4. Value Creation Analysis

18.8.4.11. TILs (Intima Bioscience)
18.8.4.11.1. Target Patient Population
18.8.4.11.2. Sales Forecast
18.8.4.11.3. Net Present Value
18.8.4.11.4. Value Creation Analysis

18.8.4.12. TILs (CAR-T (Shanghai) Cell Biotechnology)
18.8.4.12.1. Target Patient Population
18.8.4.12.2. Sales Forecast (USD Million)
18.8.4.12.3. Net Present Value (USD Million)
18.8.4.12.4. Value Creation Analysis

19. PROMOTIONAL ANALYSIS
19.1. Chapter Overview
19.2. Channels used for Promotional Campaigns
19.3. Summary of Product Website Analysis
19.4. Summary of Patient Support Services and Informative Downloads

19.5. KYMRIAH®: Promotional Analysis
19.5.1. Drug Overview
19.5.2. Product Website Analysis
19.5.2.1. Messages for Healthcare Professionals
19.5.2.2. Messages for Patients
19.5.3. Patient Support Services and Informative Downloads
19.5.4. Other Promotional Activities
19.5.4.1. Presence in Conferences

19.6. YESCARTA®: Promotional Analysis
19.6.1. Drug Overview
19.6.2. Product Website Analysis
19.6.2.1. Messages for Healthcare Professionals
19.6.2.2. Messages for Patients
19.6.3. Patient Support Services and Informative Downloads
19.6.4. Other Promotional Activities
19.6.4.1. Presence in Conferences

20. COMPANY PROFILES
20.1. Chapter Overview
20.2. Adaptimmune Therapeutics
20.3. Autolus
20.4. bluebird bio
20.5. CARsgen Therapeutics
20.6. Celgene
20.7. Cell Medica
20.8. Cellectis
20.9. Cellular Biomedicine Group
20.10. Immunocore
20.11. Innovative Cellular Therapeutics
20.12. Iovance Biotherapeutics
20.13. Kite Pharma
20.14. Lion TCR
20.15. Noile-Immune Biotech
20.16. Novartis
20.17. Shanghai GeneChem
20.18. Sinobioway Cell Therapy
20.19. Takara Bio
20.20. Unum Therapeutics
20.21. ZIOPHARM Oncology

21. CONCLUDING REMARKS
21.1. Chapter Overview
21.2. Key Takeaways

22. EXECUTIVE INSIGHTS
22.1. Chapter Overview
22.2. Cell Therapies
22.2.1 Interview Transcript: Tim Oldham, Chief Executive Officer 
22.3. Glycostem Therapeutics
22.3.1 Interview Transcript: Troels Jordansen, Chief Executive Officer
22.4. Gracell Biotechnologies
22.4.1 Interview Transcript: Wei (William) Cao, Chief Executive Officer
22.5. Lion TCR
22.5.1 Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
22.6. TxCell
22.6.1 Interview Transcript: Miguel Forte, Chief Operating Officer
22.7. Kite Pharma
22.7.1 Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
22.8. Celyad
22.8.1 Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys 
22.9. Iovance Biotherapeutics
22.9.1 Interview Transcript: Peter Ho, Director, Process Development
22.10. Waisman Biomanufacturing
22.10.1 Interview Transcript: Brian Dattilo, Manager of Business Development
22.11. Theravectys
22.11.1 Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
22.12. Changhai Hospital
22.12.1 Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
22.13. University of Colorado
22.13.1 Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

23. APPENDIX 1: TABULATED DATA

24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Key Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Historical Development Timeline of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR-T Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR-T Cell Therapies
Figure 3.11 TCR-based Therapies: Development Process
Figure 3.12 TIL-based Therapies: Development Process
Figure 3.13 T-Cell Immunotherapies: Benefits and Key Challenges
Figure 4.1 Social Media Analysis: Historical Trend on Twitter, January 2012-2019
Figure 4.2 Social Media Analysis: Trending Words / Phrases on Twitter
Figure 4.3 Social Media Analysis: Most Popular Drugs on Twitter
Figure 4.4 Social Media Analysis: Most Prolific Authors on Twitter
Figure 4.5 Social Media Analysis: Distribution by Average Number of Likes, Re-tweets and Comments Related to T-cell Immunotherapy
Figure 4.6 Social Media Analysis: Most Popular Indications and Target Antigen
Figure 5.1 T-Cell Immunotherapies: Distribution by Type of Product
Figure 5.2 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 5.3 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 5.4 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 5.5 CAR-T Cell Therapies: Distribution by Popular Target Indication
Figure 5.6 CAR-T Cell Therapies: Distribution by Popular Target Antigen
Figure 5.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Figure 5.8 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 5.9 CAR-T Cell Therapies: Distribution by Dose Frequency
Figure 5.10 CAR-T Cell Therapies: Distribution by Patient Segment
Figure 5.11 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 5.12 Key Industry Players: Distribution by Number of CAR-T Cell Therapies in Development
Figure 5.13 Key Non-Industry Players: Distribution by Number of CAR-T Cell Therapies in Development
Figure 5.14 TCR-based Therapies: Distribution by Type of Developer
Figure 5.15 TCR-based Therapies: Distribution by Phase of Development
Figure 5.16 TCR-based Therapies: Distribution by Therapeutic Area
Figure 5.17 TCR-based Therapies: Distribution by Popular Target Indication
Figure 5.18 TCR-based Therapies: Distribution by Popular Target Antigen
Figure 5.19 TCR-based Therapies: Distribution by Source of T-Cells
Figure 5.20 TCR-based Therapies: Distribution by Route of Administration
Figure 5.21 TCR-based Therapies: Distribution by Dose Frequency
Figure 5.22 TCR-based Therapies: Distribution by Patient Segment
Figure 5.23 TCR-based Therapies: Distribution by Type of Therapy
Figure 5.24 Key Industry Players: Distribution by Number of TCR-based Therapies in Development
Figure 5.25 Key Non-Industry Players: Distribution by Number of TCR-based Therapies in Development
Figure 5.26 TIL-based Therapies: Distribution by Type of Developer
Figure 5.27 TIL-based Therapies: Distribution by Phase of Development
Figure 5.28 TIL-based Therapies: Distribution by Therapeutic Area
Figure 5.29 TIL-based Therapies: Distribution by Popular Target Indication
Figure 5.30 TIL-based Therapies: Distribution by Source of T-Cells
Figure 5.31 TIL-based Therapies: Distribution by Route of Administration
Figure 5.32 TIL-based Therapies: Distribution by Dose Frequency
Figure 5.33 TIL-based Therapies: Distribution by Patient Segment
Figure 5.34 TIL-based Therapies: Distribution by Type of Therapy
Figure 5.35 Key Industry Players: Distribution by Number of TIL-based Therapies in Development
Figure 5.36 Key Non-Industry Players: Distribution by Number of TIL-based Therapies in Development
Figure 6.1 T-Cell Immunotherapies: Distribution by Popular Targets related to Hematological Malignancies
Figure 6.2 T-Cell Immunotherapies: Distribution by Popular Targets related to Solid Tumor
Figure 6.3 CAR-T Cell Therapies: Geographical Distribution of Key Opinion Leaders
Figure 6.4 CAR-T Cell Therapies: Prominent Key Opinion Leaders
Figure 6.5 TCR-based Therapies: Geographical Distribution of Key Opinion Leaders
Figure 6.6 TCR-based Therapies: Prominent Key Opinion Leaders
Figure 6.7 TIL-based Therapies: Geographical Distribution of Key Opinion Leaders
Figure 6.8 TIL-based Therapies: Prominent Key Opinion Leaders
Figure 6.9 CAR-Construction: Distribution by Generation of CAR-T Therapies
Figure 6.10 CAR-Construction: Distribution by Type of scFv Antibody used in CAR-T Therapies
Figure 6.11 CAR-Construction: Distribution by Type of Vector
Figure 6.12 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 7.1 CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2 CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography, Pre-2016 and Post-2016
Figure 8.1 Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 10.1 Nantes University Hospital’s TIL Therapy: Production Procedure
Figure 11.1 Leukemia: Classification
Figure 11.2 Leukemia: Global Epidemiological Distribution
Figure 11.3 Lymphoma: Global Epidemiological Distribution
Figure 11.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 11.5 Melanoma: Global Epidemiological Distribution
Figure 11.6 Lung Cancers: Classification
Figure 11.7 Lung Cancer: Global Epidemiological Distribution
Figure 11.8 Pancreatic Cancer: Global Epidemiological Distribution
Figure 11.9 Liver Cancer: Global Epidemiological Distribution
Figure 11.10 Breast Cancer: Global Epidemiological Distribution
Figure 11.11 Ovarian Cancer: Global Epidemiological Distribution
Figure 11.12 Bladder Cancer: Global Epidemiological Distribution
Figure 11.13 Kidney Cancer: Global Epidemiological Distribution
Figure 12.1 Genome Editing Technologies: Applications
Figure 12.2 Genome Editing: Emerging Technology Platforms Used in T-Cell Therapies
Figure 12.3 Gene Editing Platforms: Competitiveness Distribution
Figure 12.4 T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
Figure 12.5 Cellectis: Properties of Enhanced T-Cell Platform
Figure 12.6 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 13.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2005-2020
Figure 13.2 Partnerships and Collaborations: Year-Wise Trend of Industry vs Non-Industry Partnerships, 2005-2020
Figure 13.3 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.4 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2017 and Post-2017
Figure 13.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 13.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Figure 13.7 Partnerships and Collaborations: Distribution by Type of Industry
Figure 13.8 Partnerships and Collaborations: Distribution by Type of Product and Type of Industry
Figure 13.9 Partnerships and Collaborations: Distribution by Individual Products
Figure 13.10 Partnerships and Collaborations: Most Active Industry Players
Figure 13.11 Partnerships and Collaborations: Most Active Non-Industry Players
Figure 13.12 Partnerships and Collaborations: Most Active Contract Manufacturers
Figure 13.13 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution of Manufacturing Agreements
Figure 13.14 Partnerships and Collaborations: Regional Distribution
Figure 13.15 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 14.1 Funding and Investment Analysis: Distribution of Cumulative Number of Instances by Year, Pre-2013 - 2020
Figure 14.2 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, Pre 2013-2020 (USD Million)
Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre 2013-2020
Figure 14.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, Pre 2013-2020 (USD Million)
Figure 14.5 Funding and Investment Analysis: Distribution of Amount Invested across Different Types of Products
Figure 14.6 Most Active Players: Distribution by Number of Funding Instances
Figure 14.7 Funding and Investment Analysis: Distribution of Amount Invested across Different Types of Investors
Figure 14.8 Most Active Investors: Distribution by Number of Funding Instances
Figure 14.9 Funding and Investment Analysis: Distribution by Geography
Figure 14.10 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
Figure 15.1 Other T-Cell Immunotherapies: Distribution by Phase of Development
Figure 15.2 Other T-Cell Immunotherapies: Distribution by Target Therapeutic Area
Figure 15.3 Other T-Cell Immunotherapies: Distribution by Types of T-Cells
Figure 15.4 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Figure 15.5 Treg Cells: Functions
Figure 16.1 Cell Therapy: Steps for Manufacturing
Figure 16.2 Cell Therapy: Centralized Manufacturing Model
Figure 16.3 Decentralized Manufacturing: Process Model
Figure 16.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 16.5 Cell Therapy Manufacturing: Challenges and Drivers
Figure 16.6 Cell Therapy: Potency as Critical Quality Attribute
Figure 16.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 16.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 17.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 18.1 Overall T-Cell Immunotherapy Market, 2019-2030 (USD Billion)
Figure 18.2 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2030 (USD Billion)
Figure 18.3 T-Cell Immunotherapy Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Figure 18.4 T-Cell Immunotherapy Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
Figure 18.5 T-Cell Immunotherapy Market: Distribution by Key Players, 2025 and 2030 (USD Billion)
Figure 18.6 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Figure 18.7 Overall CAR-T Cell Therapies Market, 2020-2030 (USD Billion)
Figure 18.8 CAR-T Cell Therapies Market: Distribution by Target Indication(s) (USD Billion)
Figure 18.9 CAR-T Cell Therapies Market: Distribution by Target Antigen(s) (USD Billion)
Figure 18.10 CAR-T Cell Therapies Market: Distribution by Key Players (USD Billion)
Figure 18.11 CAR-T Cell Therapies Market: Distribution by Geography (USD Billion)
Figure 18.12 KYMRIAH® (Novartis): Current Status of Development
Figure 18.13 KYMRIAH® (Novartis): Sales Forecast, till 2030 (USD Million)
Figure 18.14 YESCARTA® (Gilead Sciences): Current Status of Development
Figure 18.15 YESCARTA® (Gilead Sciences): Sales Forecast, till 2030 (USD Million)
Figure 18.16 Tecartus® / Brexucabtagene Autoleucel (Gilead Sciences): Current Status of Development
Figure 18.17 Tecartus® / Brexucabtagene Autoleucel: Sales Forecast, till 2030 (USD Million)
Figure 18.18 Idecabtagene Vicleucel / bb2121 (bluebird bio / Celgene): Current Status of Development
Figure 18.19 Idecabtagene Vicleucel / bb2121 (bluebird bio / Celgene): Sales Forecast, till 2030 (USD Million)
Figure 18.20 Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech /Janssen): Current Status of Development
Figure 18.21 Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech /Janssen): Sales Forecast, till 2030 (USD Million)
Figure 18.22 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Current Status of Development
Figure 18.23 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Sales Forecast, till 2030 (USD Million)
Figure 18.24 MB-CART19.1 (Miltenyi Biotec): Current Status of Development
Figure 18.25 MB-CART19.1 (Miltenyi Biotec): Sales Forecast, till 2030 (USD Million)
Figure 18.26 Descartes-11 (Cartesian Therapeutics): Current Status of Development
Figure 18.27 Descartes-11 (Cartesian Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 18.28 MB-102 (Mustang Bio): Current Status of Development
Figure 18.29 MB-102 (Mustang Bio): Sales Forecast, till 2030 (USD Million)
Figure 18.30 huCART19 / CTL119 (Novartis): Current Status of Development
Figure 18.31 huCART19 / CTL119 (Novartis): Sales Forecast, till 2030 (USD Million)
Figure 18.32 CD19 CAR-T (Sinobioway Cell Therapy): Current Status of Development
Figure 18.33 CD19 CAR-T (Sinobioway Cell Therapy): Sales Forecast, till 2030 (USD Million)
Figure 18.34 AUTO1 (Autolus): Current Status of Development
Figure 18.35 AUTO1 (Autolus): Sales Forecast, till 2030 (USD Million)
Figure 18.36 AUTO3 (Autolus): Current Status of Development
Figure 18.37 AUTO3 (Autolus): Sales Forecast, till 2030 (USD Million)
Figure 18.38 AUTO4 (Autolus): Current Status of Development
Figure 18.39 AUTO4 (Autolus): Sales Forecast, till 2030 (USD Million)
Figure 18.40 GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 18.41 GPC3 CAR-T (Shanghai GeneChem): Sales Forecast, till 2030 (USD Million)
Figure 18.42 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 18.43 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Sales Forecast, till 2030 (USD Million)
Figure 18.44 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 18.45 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Sales Forecast, till 2030 (USD Million)
Figure 18.46 CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 18.47 CD19 CAR-T (Shanghai Bioray Laboratory): Sales Forecast, till 2030 (USD Million)
Figure 18.48 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
Figure 18.49 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Sales Forecast, till 2030 (USD Million)
Figure 18.50 PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 18.51 PCAR-019 (PersonGen BioTherapeutics): Sales Forecast, till 2030 (USD Million)
Figure 18.52 TBI-1501 (Takara Bio): Current Status of Development
Figure 18.53 TBI-1501 (Takara Bio): Sales Forecast, till 2030 (USD Million)
Figure 18.54 IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
Figure 18.55 IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Sales Forecast, till 2030 (USD Million)
Figure 18.56 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Current Status of Development
Figure 18.57 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Sales Forecast, till 2030 (USD Million)
Figure 18.58 BinD19 (Shenzhen BinDeBio): Current Status of Development
Figure 18.59 BinD19 (Shenzhen BinDeBio): Sales Forecast, till 2030 (USD Million)
Figure 18.60 CARCIK-CD19 (Formula Pharmaceuticals): Current Status of Development
Figure 18.61 CARCIK-CD19 (Formula Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Figure 18.62 EGFR CART (The Beijing Pregene Science and Technology): Current Status of Development
Figure 18.63 EGFR CART (The Beijing Pregene Science and Technology): Sales Forecast, till 2030 (USD Million)
Figure 18.64 Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Current Status of Development
Figure 18.65 Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Sales Forecast, till 2030 (USD Million)
Figure 18.66 PBCAR269A (Precision BioSciences): Current Status of Development
Figure 18.67 PBCAR269A (Precision BioSciences): Sales Forecast, till 2030 (USD Million)
Figure 18.68 CD123 CAR-T cells (Chongqing Precision Biotech): Current Status of Development
Figure 18.69 CD123 CAR-T cells (Chongqing Precision Biotech): Sales Forecast, till 2030 (USD Million)
Figure 18.70 BCMA CAR-T (Chongqing Precision Biotech): Current Status of Development
Figure 18.71 BCMA CAR-T (Chongqing Precision Biotech): Sales Forecast, till 2030 (USD Million)
Figure 18.72 CEA CAR-T cells (Chongqing Precision Biotech): Current Status of Development
Figure 18.73 CEA CAR-T cells (Chongqing Precision Biotech): Sales Forecast, till 2030 (USD Million)
Figure 18.74 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Current Status of Development
Figure 18.75 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Figure 18.76 P-BCMA-101 (Poseida Therapeutics): Current Status of Development
Figure 18.77 P-BCMA-101 (Poseida Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 18.78 CD19 CAR-T (iCarTAB BioMed): Current Status of Development
Figure 18.79 CD19 CAR-T (iCarTAB BioMed): Sales Forecast, till 2030 (USD Million)
Figure 18.80 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
Figure 18.81 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Sales Forecast, till 2030 (USD Million)
Figure 18.82 BPX-601 (Bellicum Pharmaceuticals): Current Status of Development
Figure 18.83 BPX-601 (Bellicum Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Figure 18.84 MUC1 CAR-T (PersonGen BioTherapeutics (Suzhou)): Current Status of Development
Figure 18.85 MUC1 CAR-T (PersonGen BioTherapeutics (Suzhou)): Sales Forecast, till 2030 (USD Million)
Figure 18.86 Overall TCR-based Therapies Market, 2019-2030 (USD Billion)
Figure 18.87 TCR-Based Therapies Market: Distribution by Target Indication(s) (USD Billion)
Figure 18.88 TCR-Based Therapies Market: Distribution by Target Antigen(s) (USD Billion)
Figure 18.89 TCR-Based Therapies Market: Key Players (USD Billion)
Figure 18.90 TCR-Based Therapies Market: Distribution by Geography (USD Billion)
Figure 18.91 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Current Status of Development
Figure 18.92 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Sales Forecast, till 2030 (USD Million)
Figure 18.93 IMCgp100 (Immunocore): Current Status of Development
Figure 18.94 IMCgp100 (Immunocore): Sales Forecast, till 2030 (USD Million)
Figure 18.95 ADP-A2M4 (Adaptimmune Therapeutics): Current Status of Development
Figure 18.96 ADP-A2M4 (Adaptimmune Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 18.97 TBI-1301 (Takara Bio): Current Status of Development
Figure 18.98 TBI-1301 (Takara Bio): Sales Forecast, till 2030 (USD Million)
Figure 18.99 ALT 801 (Altor BioScience): Current Status of Development
Figure 18.100 ALT 801 (Altor BioScience): Sales Forecast, till 2030 (USD Million)
Figure 18.101 JTCR016 (Juno Therapeutics): Current Status of Development
Figure 18.102 JTCR016 (Juno Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 18.103 LioCyx (Lion TCR): Current Status of Development
Figure 18.104 LioCyx (Lion TCR): Sales Forecast, till 2030 (USD Million)
Figure 18.105 YT-E001 (China Immunotech): Current Status of Development
Figure 18.106 YT-E001 (China Immunotech): Sales Forecast, till 2030 (USD Million)
Figure 18.107 MDG1011 (Medigene): Current Status of Development
Figure 18.108 MDG1011 (Medigene): Sales Forecast, till 2030 (USD Million)
Figure 18.109 TC-110 (TCR2 Therapeutics): Current Status of Development
Figure 18.110 TC-110 (TCR2 Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 18.111 LMBP2-specific TCR-T (TCR CURE Biopharma Technology): Current Status of Development
Figure 18.112 LMBP2-specific TCR-T (TCR CURE Biopharma Technology): Sales Forecast, till 2030 (USD Million)
Figure 18.113 Overall TIL-based Therapies Market, 2019-2030 (USD Billion)
Figure 18.114 TIL-Based Therapies Market: Distribution by Target Indication(s) (USD Billion)
Figure 18.115 TIL-Based Therapies Market: Key Players (USD Billion)
Figure 18.116 TIL-Based Therapies Market: Distribution by Geography (USD Billion)
Figure 18.117 TILs (Nantes University Hospital): Current Status of Development
Figure 18.118 TILs (Nantes University Hospital): Sales Forecast, till 2030) (USD Million)
Figure 18.119 TILs (Netherland Cancer Institute): Current Status of Development
Figure 18.120 TILs (Netherland Cancer Institute): Sales Forecast, till 2030 (USD Million)
Figure 18.121 Lifileucel (LN-144) (Iovance Biotherapeutics): Current Status of Development
Figure 18.122 Lifileucel (LN-144) (Iovance Biotherapeutics): Sales Forecast, till 2030 (USD Million)
Figure 18.123 LN-145 (Iovance Biotherapeutics): Current Status of Development
Figure 18.124 LN-145 (Iovance Biotherapeutics): Sales Forecast, till 2030 (USD Million)
Figure 18.125 LTX-315 and TILs (Lytix Biopharma): Current Status of Development
Figure 18.126 LTX-315 and TILs (Lytix Biopharma): Sales Forecast, till 2030 (USD Million)
Figure 18.127 IOV-2001 (Iovance Biotherapeutics): Current Status of Development
Figure 18.128 IOV-2001 (Iovance Biotherapeutics): Sales Forecast, till 2030 (USD Million)
Figure 18.129 Allogeneic Donor Lymphocytes (Amgen): Current Status of Development
Figure 18.130 Allogeneic Donor Lymphocytes (Amgen): Sales Forecast, till 2030 (USD Million)
Figure 18.131 Donor Lymphocyte Infusion (Incyte): Current Status of Development
Figure 18.132 Donor Lymphocyte Infusion (Incyte): Sales Forecast, till 2030 (USD Million)
Figure 18.133 TILs (Bristol-Myers Squibb): Current Status of Development
Figure 18.134 TILs (Bristol-Myers Squibb): Sales Forecast, till 2030 (USD Million)
Figure 18.135 UTIL-01 and CoTIL-01 (Immetacyte): Current Status of Development
Figure 18.136 UTIL-01 and CoTIL-01 (Immetacyte): Sales Forecast, till 2030 (USD Million)
Figure 18.137 TILs (Intima Bioscience): Current Status of Development
Figure 18.138 TILs (Intima Bioscience): Sales Forecast, till 2030 (USD Million)
Figure 18.139 TILs (CAR-T (Shanghai) Cell Biotechnology): Current Status of Development
Figure 18.140 TILs (CAR-T (Shanghai) Cell Biotechnology): Sales Forecast, till 2030 (USD Million)
Figure 19.1 Promotional / Marketing Strategy: Channels Used
Figure 19.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 19.3 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 19.4 Product Website Analysis: KYMRIAH®, Message for Healthcare Professionals
Figure 19.5 Product Website Analysis: KYMRIAH®, Message for Patients
Figure 19.6 Product Website Analysis: KYMRIAH®, Patient Support Program
Figure 19.7 KYMRIAH®: Presence in Conferences
Figure 19.8 Product Website Analysis: YESCARTA®, Message for Healthcare Professionals
Figure 19.9 Product Website Analysis: YESCARTA®, Messages for Patients
Figure 19.10 Product Website Analysis: YESCARTA®, Kite Konnect
Figure 19.11 Product Website Analysis: YESCARTA®, Platform for Reporting Adverse Events / Product Complaints and Requesting Medical Information
Figure 19.12 YESCARTA®: Presence in Conferences
Figure 21.1 T-Cell Immunotherapy Market: Concluding Remarks

List Of Tables

Table 3.1 Types of Immunotherapies and Affiliated Mechanism of Action
Table 3.2 FDA Approved Antibody Based Cancer Therapeutics
Table 3.3 Key Characteristics of CAR-T Cells
Table 3.4 Comparison of First and Second-Generation CAR-Ts
Table 3.5 CD19 CAR-T Cells: Preclinical Results
Table 3.6 Other Targets Under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 3.7 CAR-T Cell and TCR-based Therapies: Key Differences
Table 5.1 T-Cell Immunotherapies: Overall Market Overview
Table 5.2 CAR-T Cell Therapies: Overall Market Overview
Table 5.3 TCR-based Therapies: Overall Market Overview
Table 5.4 TIL-based Therapies: Overall Market Overview
Table 6.1 CD19 CAR-T Cell Therapies: Competitive Landscape
Table 6.2 CD19 CAR-T Cell Therapies: Clinical Outcomes
Table 6.3 BCMA CAR-T Cell Therapies: Competitive Landscape
Table 6.4 BCMA CAR-T Cell Therapies: Clinical Outcomes
Table 6.5 Meso CAR-T Cell Therapies: Competitive Landscape
Table 6.6 Meso CAR-T Cell Therapies: Clinical Outcomes
Table 6.7 GD2 CAR-T Cell Therapies: Competitive Landscape
Table 6.8 GD2 CAR-T Cell Therapies: Clinical Outcomes
Table 6.9 CAR-T Cell Therapies: Principal Investigators
Table 6.10 TCR-based Therapies: Principal Investigators
Table 6.11 TIL-based Therapies: Principal Investigators
Table 6.12 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 7.1 CAR-T Cell Therapies: List of Clinical Trials
Table 7.2 Advanced Phase CAR-T Cell Therapies in China
Table 8.1 KYMRIAH®: Clinical Studies
Table 8.2 KYMRIAH®: Clinical Trial Endpoints (ALL)
Table 8.3 KYMRIAH®: Clinical Trial Endpoints (CLL / MM / NHL / FL)
Table 8.4 YESCARTA®: Clinical Studies
Table 8.5 YESCARTA®: Clinical Trial Endpoints
Table 8.6 Tecartus / Brexucabtagene Autoleucel: Clinical Studies
Table 8.7 Tecartus / Brexucabtagene Autoleucel: Clinical Trial Endpoints
Table 8.8 JCAR Series: Molecules in Clinical Development
Table 8.9 JCAR: CAR-T Design
Table 8.10 JCAR014: Clinical Studies
Table 8.11 JCAR017: Clinical Studies
Table 8.13 JCAR018: Clinical Studies
Table 8.14 JCARH125: Clinical Studies
Table 8.15 JCAR Series: Clinical Trial Endpoints (Phase I/II / Phase II / Phase III)
Table 8.16 JCAR Series: Clinical Trial Endpoints (Phase I)
Table 8.17 JCAR: Dosage Regimen
Table 8.18 Idecabtagene Vicleucel / bb2121: Clinical Studies
Table 8.19 Idecabtagene Vicleucel / bb2121: Clinical Trial Endpoints
Table 8.20 Ciltacabtagene Autoleucel / LCAR-B38M CAR-T: Clinical Studies
Table 8.21 Ciltacabtagene Autoleucel / LCAR-B38M CAR-T: Clinical Trial Endpoints
Table 8.22 Takara Bio’s CD19 CAR-T: Clinical Studies
Table 8.23 Takara Bio’s CD19 CAR-T: Clinical Trial Endpoints
Table 8.24 TBI-1501: Dosage Regimen
Table 8.25 AUTO2: Clinical Studies
Table 8.26 AUTO3: Clinical Studies
Table 8.27 AUTO4: Clinical Studies
Table 8.28 Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.29 Sinobioway Cell Therapy’s CD19 CAR-T Therapy: Clinical Studies
Table 8.30 Sinobioway Cell Therapy’s EPCAM CAR-T Therapy: Clinical Studies
Table 8.31 Sinobioway Cell Therapy’s Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.32 Phase I/II or Phase II CAR-T Cell Therapies from the Industry Players
Table 9.1 NY-ESO TCR: Clinical Studies
Table 9.2 MAGE-A10: Clinical Studies
Table 9.3 MAGE A-4: Clinical Studies
Table 9.4 AFP T-Cell: Clinical Studies
Table 9.5 NY-ESO TCR: Clinical Trial Endpoints
Table 9.6 MAGE A-10 / MAGE A-4 / AFP TCR: Clinical Trial Endpoints
Table 9.7 IMCgp100: Clinical Studies
Table 9.8 IMCgp100: Clinical Trial Endpoints
Table 9.9 ALT-801: Clinical Studies
Table 9.10 ALT-801: Clinical Trial Endpoints
Table 9.11 JTCR016: Clinical Studies
Table 9.12 JTCR016: Clinical Trial Endpoints
Table 9.13 WT1 TCR: Clinical Studies
Table 9.14 WT1 TCR: Clinical Trial Endpoints
Table 9.15 TBI-1301: Current Status of Development
Table 9.16 TBI-1301: Clinical Trial Endpoints
Table 9.17 MDG1011: Current Status of Development
Table 9.18 MDG1011: Clinical Trial Endpoints
Table 10.1 LN-144: Clinical Studies
Table 10.2 LN-144: Clinical Trial Endpoints
Table 10.3 LN-145: Current Status of Development
Table 10.4 LN-145: Clinical Trial Endpoints
Table 10.5 LN-144: Patent Portfolio
Table 10.6 Nantes University Hospital’s TIL Therapy: Clinical Trial Endpoints
Table 10.7 Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Endpoints
Table 11.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 11.2 Leukemia: List of Marketed Targeted Therapeutics
Table 11.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 11.4 T-Cell Immunotherapies: Targets Under Investigation for Leukemia
Table 11.5 T-Cell Immunotherapies: Targets Under Investigation for Lymphoma
Table 11.6 Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 11.7 T-Cell Immunotherapies: Targets Under Investigation for Multiple Myeloma
Table 11.8 Melanoma: List of Marketed Targeted Therapeutics
Table 11.9 TIL-based Therapy: Historical Development of Treatment Protocols for Melanoma at the National Cancer Institute
Table 11.10 T-Cell Immunotherapies: TIL-based Therapies Under Investigation for Metastatic Melanoma
Table 11.11 Lung Cancer: List of Marketed Targeted Therapeutics
Table 11.12 T-Cell Immunotherapies: Targets Under Investigation for Lung Cancer
Table 11.13 Pancreatic Cancer: List of Marketed Targeted Therapeutics
Table 11.14 T-Cell Immunotherapies: Targets Under Investigation for Pancreatic Cancer
Table 11.15 Liver Cancer: List of Marketed Targeted Therapeutics
Table 11.16 CAR-T Cell Therapies: Targets Under Investigation for Liver Cancer
Table 11.17 TCR-based Therapies: Targets Under Investigation for Liver Cancer
Table 11.18 Breast Cancer: List of Marketed Targeted Therapeutics
Table 11.19 CAR-T Cell Therapies: Targets Under Investigation for Breast Cancer
Table 11.20 TCR-based Therapies: Targets Under Investigation for Breast Cancer
Table 11.21 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 11.22 T-Cell Immunotherapies: Targets Under Investigation for Ovarian Cancer
Table 11.23 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 11.24 Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 12.1 Editas Medicine: CRISPR / Cas9 Technology, Research Publications
Table 12.2 Editas Medicine: Funding Instances
Table 12.3 Editas Medicine: Partnerships and Collaborations
Table 12.4 Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
Table 12.5 Intellia Therapeutics: Funding Instances
Table 11.6 Intellia Therapeutics: Partnerships and Collaborations
Table 11.7 CRISPR Therapeutics: CRIPSR / Cas9 Technology, Research Publications
Table 12.8 CRISPR Therapeutics: Funding Instances
Table 12.9 CRISPR Therapeutics: Partnerships and Collaborations
Table 12.10 Beam Therapeutics: Funding Instances
Table 12.11 Beam Therapeutics: Partnerships and Collaborations
Table 12.12 Gracell Biotechnologies: Funding Instances
Table 12.13 Cellectis: Funding Instances
Table 12.14 Cellectis: Partnerships and Collaborations
Table 12.15 bluebird bio: megaTAL Technology, Research Publications
Table 12.16 bluebird bio: Funding Instances
Table 12.17 bluebird bio: Partnerships and Collaborations
Table 12.18 Sangamo Therapeutics: Funding Instances
Table 12.19 Sangamo Therapeutics: Partnerships and Collaborations
Table 12.20 Unum Therapeutics: Funding Instances
Table 12.21 Unum Therapeutics: Partnerships and Collaborations
Table 12.22 Celyad: Funding Instances
Table 12.23 Celyad: Partnerships and Collaborations
Table 12.24 Glycostem: Funding Instances
Table 12.25 Glycostem: Partnerships and Collaborations
Table 12.26 Intrexon: Funding Instances
Table 12.27 Intrexon: Partnerships and Collaborations
Table 12.28 Bellicum Pharmaceuticals: Key Switch Technologies
Table 12.29 Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 12.30 Bellicum Pharmaceuticals: Funding Instances
Table 12.31 Bellicum Pharmaceuticals: Collaborations
Table 12.32 Theravectys: Funding Instances
Table 12.33 Technologies for CAR-T Safety Enhancement
Table 12.34 Formula Pharmaceuticals: Collaborations
Table 13.1 T-Cell Immunotherapies Market: Partnerships and Collaborations, 2005-2020 (till October)
Table 14.1 T-Cell Immunotherapies: Funding and Investments, Pre-2010 to 2020
Table 14.2 T-Cell Immunotherapies: Summary of Investments
Table 15.1 List of Other Novel T-Cell Immunotherapies
Table 15.2 Treg Cells: Properties
Table 16.1 Assessment Strategies for Different Manufacturing Processes
Table 16.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 16.3 Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 16.4 Cell Therapy Manufacturing: Contract Manufacturers
Table 17.1 Price of Marketed Gene / Cell Therapies
Table 17.2 Price of Marketed Targeted Drugs
Table 17.3 T-Cell Immunotherapies: Expert Opinions on Pricing
Table 17.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 18.1 T-Cell Immunotherapies: List of Forecasted Molecules
Table 18.2 Kymriah (Novartis): Net Present Value (USD Million)
Table 18.3 Kymriah (Novartis): Value Creation Analysis (USD Million)
Table 18.4 Yescarta (Gilead Sciences): Net Present Value (USD Million)
Table 18.5 Yescarta (Gilead Sciences): Value Creation Analysis (USD Million)
Table 18.6 Tecartus® / Brexucabtagene Autoleucel (Gilead Sciences): Net Present Value (USD Million)
Table 18.7 Tecartus® / Brexucabtagene Autoleucel (Gilead Sciences): Value Creation Analysis (USD Million)
Table 18.8 Idecabtagene Vicleucel / bb2121 (bluebird bio / Celgene): Net Present Value (USD Million)
Table 18.9 Idecabtagene Vicleucel / bb2121 (bluebird bio / Celgene): Value Creation Analysis (USD Million)
Table 18.10 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Net Present Value (USD Million)
Table 18.11 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Value Creation Analysis (USD Million)
Table 18.12 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Net Present Value (USD Million)
Table 18.13 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Value Creation Analysis (USD Million)
Table 18.14 MB-CART19.1 (Miltenyi Biotec): Net Present Value (USD Million)
Table 18.15 MB-CART19.1 (Miltenyi Biotec): Value Creation Analysis (USD Million)
Table 18.14 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 18.16 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 18.17 MB-102 (Mustang Bio): Net Present Value (USD Million)
Table 18.18 MB-102 (Mustang Bio): Value Creation Analysis (USD Million)
Table 18.19 huCART19 / CTL119 (Novartis): Net Present Value (USD Million)
Table 18.20 huCART19 / CTL119 (Novartis): Value Creation Analysis (USD Million)
Table 18.21 CD19 CAR-T (Sinobioway Cell Therapy): Net Present Value (USD Million)
Table 18.22 CD19 CAR-T (Sinobioway Cell Therapy): Value Creation Analysis (USD Million)
Table 18.23 AUTO1 (Autolus): Net Present Value (USD Million)
Table 18.24 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 18.25 AUTO2 (Autolus): Net Present Value (USD Million)
Table 18.26 AUTO2 (Autolus): Value Creation Analysis (USD Million)
Table 18.27 AUTO3 (Autolus): Net Present Value (USD Million)
Table 18.28 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 18.29 GPC3 CAR-T (Shanghai GeneChem): Net Present Value (USD Million)
Table 18.30 GPC3 CAR-T (Shanghai GeneChem): Value Creation Analysis (USD Million)
Table 18.31 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 18.32 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 18.33 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 18.34 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 18.35 CD19 CAR-T (Shanghai Bioray Laboratory): Net Present Value (USD Million)
Table 18.36 CD19 CAR-T (Shanghai Bioray Laboratory): Value Creation Analysis (USD Million)
Table 18.37 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 18.38 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 18.39 PCAR-019 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 18.40 PCAR-019 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 18.41 TBI-1501 (Takara Bio): Net Present Value (USD Million)
Table 18.42 TBI-1501 (Takara Bio): Value Creation Analysis (USD Million)
Table 18.43 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 18.44 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
Table 18.45 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD Million)
Table 18.46 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 18.47 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 18.48 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 18.49 CARCIK-CD19 (Formula Pharmaceuticals): Net Present Value (USD Million)
Table 18.50 CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 18.51 EGFR CART (The Beijing Pregene Science and Technology): Net Present Value (USD Million)
Table 18.52 EGFR CART (The Beijing Pregene Science and Technology): Value Creation Analysis (USD Million)
Table 18.53 ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Net Present Value (USD Million)
Table 18.54 ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Value Creation Analysis (USD Million)
Table 18.55 PBCAR269A (Precision BioSciences): Net Present Value (USD Million)
Table 18.56 PBCAR269A (Precision BioSciences): Value Creation Analysis (USD Million)
Table 18.57 CD123 CAR-T cells (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 18.58 CD123 CAR-T cells (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 18.59 BCMA CAR-T (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 18.60 BCMA CAR-T (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 18.61 CEA CAR-T cells (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 18.62 CEA CAR-T cells (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 18.63 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 18.64 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 18.65 P-BCMA-101 (Poseida Therapeutics): Net Present Value (USD Million)
Table 18.66 P-BCMA-101 (Poseida Therapeutics): Value Creation Analysis (USD Million)
Table 18.67 CD19 CAR-T (iCarTAB BioMed): Net Present Value (USD Million)
Table 18.68 CD19 CAR-T (iCarTAB BioMed): Value Creation Analysis (USD Million)
Table 18.69 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 18.70 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 18.71 BPX-601 (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 18.72 BPX-601 (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 18.73 MUC1 CAR-T (PersonGen BioTherapeutics (Suzhou)) Net Present Value (USD Million)
Table 18.74 MUC1 CAR-T (PersonGen BioTherapeutics (Suzhou)) Value Creation Analysis (USD Million)
Table 18.75 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Net Present Value (USD Million)
Table 18.76 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Value Creation Analysis (USD Million)
Table 18.77 IMCgp100 (Immunocore): Net Present Value (USD Million)
Table 18.78 IMCgp100 (Immunocore): Value Creation Analysis (USD Million)
Table 18.79 ADP-A2M4 (Adaptimmune Therapeutics): Net Present Value (USD Million)
Table 18.80 ADP-A2M4 (Adaptimmune Therapeutics): Value Creation Analysis (USD Million)
Table 18.81 TBI-1301 (Takara Bio): Net Present Value (USD Million)
Table 18.82 TBI-1301 (Takara Bio): Value Creation Analysis (USD Million)
Table 18.83 ALT 801 (Altor BioScience): Net Present Value (USD Million)
Table 18.84 ALT 801 (Altor BioScience): Value Creation Analysis (USD Million)
Table 18.85 JTCR016 (Juno Therapeutics): Net Present Value (USD Million)
Table 18.86 JTCR016 (Juno Therapeutics): Value Creation Analysis (USD Million)
Table 18.87 LioCyx (Lion TCR): Net Present Value (USD Million)
Table 18.88 LioCyx (Lion TCR): Value Creation Analysis (USD Million)
Table 18.89 YT-E001 (China Immunotech): Net Present Value (USD Million)
Table 18.90 YT-E001 (China Immunotech): Value Creation Analysis (USD Million)
Table 18.91 MDG1011 (Medigene): Net Present Value (USD Million)
Table 18.92 MDG1011 (Medigene): Value Creation Analysis (USD Million)
Table 18.93 TC-110 (TCR2 Therapeutics): Net Present Value (USD Million)
Table 18.94 TC-110 (TCR2 Therapeutics): Value Creation Analysis (USD Million)
Table 18.95 LMBP2-specific TCR-T (TCR CURE Biopharma Technology): Net Present Value (USD Million)
Table 18.96 LMBP2-specific TCR-T (TCR CURE Biopharma Technology): Value Creation Analysis (USD Million)
Table 18.97 TILs (Nantes University Hospital): Net Present Value (USD Million)
Table 18.98 TILs (Nantes University Hospital): Value Creation Analysis (USD Million)
Table 18.99 TILs (Netherland Cancer Institute): Net Present Value (USD Million)
Table 18.100 TILs (Netherland Cancer Institute): Value Creation Analysis (USD Million)
Table 18.101 Lifileucel (LN-144) (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 18.102 Lifileucel (LN-144) (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 18.103 LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 18.104 LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 18.105 LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
Table 18.106 LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
Table 18.107 IOV-2001 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 18.108 IOV-2001 (Iovance Biotherapeutics) Value Creation Analysis (USD Million)
Table 18.109 Allogeneic Donor Lymphocytes (Amgen): Net Present Value (USD Million)
Table 18.110 Allogeneic Donor Lymphocytes (Amgen): Value Creation Analysis (USD Million)
Table 18.111 Donor Lymphocyte Infusion (Incyte): Net Present Value (USD Million)
Table 18.112 Donor Lymphocyte Infusion (Incyte): Value Creation Analysis (USD Million)
Table 18.113 TILs (Bristol-Myers Squibb): Net Present Value (USD Million)
Table 18.114 TILs (Bristol-Myers Squibb): Value Creation Analysis (USD Million)
Table 18.115 UTIL-01 and CoTIL-01 (Immetacyte): Net Present Value (USD Million)
Table 18.116 UTIL-01 and CoTIL-01 (Immetacyte): Value Creation Analysis (USD Million)
Table 18.117 TILs (Intima Bioscience): Net Present Value (USD Million)
Table 18.118 TILs (Intima Bioscience): Value Creation Analysis (USD Million)
Table 18.119 TILs (CAR-T (Shanghai) Cell Biotechnology): Net Present Value (USD Million)
Table 18.120 TILs (CAR-T (Shanghai) Cell Biotechnology): Value Creation Analysis (USD Million)
Table 19.1 KYMRIAH®: Drug Overview
Table 19.2 YESCARTA®: Drug Overview
Table 20.1 Adaptimmune Therapeutics: Company Profile
Table 20.2 Autolus: Company Profile
Table 20.3 bluebird bio: Company Profile
Table 20.4 CARsgen Therapeutics: Company Profile
Table 20.5 Celgene: Company Profile
Table 20.6 Cell Medica: Company Profile
Table 20.7 Cellectis: Company Profile
Table 20.8 Cellular Biomedicine Group: Company Profile
Table 20.9 Immunocore: Company Profile
Table 20.10 Innovative Cellular Therapeutics: Company Profile
Table 20.11 Iovance Biotherapeutics: Company Profile
Table 20.12 Kite Pharma: Company Profile
Table 20.13 Lion TCR: Company Profile
Table 20.14 Noile-Immune Biotech: Company Profile
Table 20.15 Novartis: Company Profile
Table 20.16 Shanghai Genechem: Company Profile
Table 20.17 Sinobioway Cell Therapy: Company Profile
Table 20.18 Takara Bio: Company Profile
Table 20.19 Unum Therapeutics: Company Profile
Table 20.20 ZIOPHARM Oncology: Company Profile
Table 23.1 T-Cell Immunotherapies: Distribution by Type of Product
Table 23.2 CAR-T Cell Therapies: Distribution by Type of Developer
Table 23.3 CAR-T Cell Therapies: Distribution by Phase of Development
Table 23.4 CAR-T Cell Therapies: Distribution by Therapeutic Area
Table 23.5 CAR-T Cell Therapies: Distribution by Popular Target Indication(s)
Table 23.6 CAR-T Cell Therapies: Distribution by Popular Target Antigen(s)
Table 23.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Table 23.8 CAR-T Cell Therapies: Distribution by Route of Administration
Table 23.9 CAR-T Cell Therapies: Distribution by Dose Frequency
Table 23.10 CAR-T Cell Therapies: Distribution by Patient Segment
Table 23.11 CAR-T Cell Therapies: Distribution by Type of Therapy
Table 23.12 Key Industry Players: Distribution by Number of CAR-T Cell Therapies in Development
Table 23.13 Key Non-Industry Players: Distribution by Number of CAR-T Cell Therapies in Development
Table 23.14 TCR-based Therapies: Distribution by Type of Developer
Table 23.15 TCR-based Therapies: Distribution by Phase of Development
Table 23.16 TCR-based Therapies: Distribution by Therapeutic Area
Table 23.17 TCR-based Therapies: Distribution by Popular Target Indications
Table 23.18 TCR-based Therapies: Distribution by Popular Target Antigens
Table 23.19 TCR-based Therapies: Distribution by Source of T-Cells
Table 23.20 TCR-based Therapies: Distribution by Route of Administration
Table 23.21 TCR-based Therapies: Distribution by Dose Frequency
Table 23.22 TCR-based Therapies: Distribution by Patient Segment
Table 23.23 TCR-based Therapies: Distribution by Type of Therapy
Table 23.24 Key Industry Players: Distribution by Number of TCR-based Therapies in Development
Table 23.25 Key Non-Industry Players: Distribution by Number of TCR-based Therapies in Development
Table 23.26 TIL-based Therapies: Distribution by Type of Developer
Table 23.27 TIL-based Therapies: Distribution by Phase of Development
Table 23.28 TIL-based Therapies: Distribution by Therapeutic Area
Table 23.29 TIL-based Therapies: Distribution by Popular Target Indications
Table 23.30 TIL-based Therapies: Distribution by Source of T-Cells
Table 23.31 TIL-based Therapies: Distribution by Route of Administration
Table 23.32 TIL-based Therapies: Distribution by Dose Frequency
Table 23.33 TIL-based Therapies: Distribution by Patient Segment
Table 23.34 TIL-based Therapies: Distribution by Type of Therapy
Table 23.35 Key Industry Players: Distribution by Number of TIL-based Therapies in Development
Table 23.36 Key Non-Industry Players: Distribution by Number of TIL-based Therapies in Development
Table 23.37 T-Cell Immunotherapies: Distribution by Popular Targets related to Hematological Malignancies
Table 23.38 T-Cell Immunotherapies: Distribution by Popular Targets related to Solid Tumor
Table 23.39 CAR-Construction: Distribution by Generation of CAR-T Cell Therapies
Table 23.40 CAR-Construction: Distribution by Type of scFv Antibody used in CAR-T Cell Therapies
Table 23.41 CAR-Construction: Distribution by Type of Vector
Table 23.42 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Table 23.43 CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 23.44 CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and Post-2016)
Table 23.45 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2005-2020
Table 23.46 Partnerships and Collaborations: Year-Wise Distribution of Industry vs Non-Industry Partnerships, 2005-2020
Table 23.47 Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.48 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2017 and Post-2017
Table 23.49 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 23.50 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Table 23.51 Partnerships and Collaborations: Distribution by Type of Industry
Table 23.52 Partnerships and Collaborations: Distribution by Type of Product and Type of Industry
Table 23.53 Partnerships and Collaborations: Distribution by Individual Products
Table 23.54 Partnerships and Collaborations: Most Active Industry Players
Table 23.55 Partnerships and Collaborations: Most Active Non-Industry Players
Table 23.56 Partnerships and Collaborations: Most Active Contract Manufacturers
Table 23.57 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution of Manufacturing Agreements
Table 23.58 Partnerships and Collaborations: Regional Distribution
Table 23.59 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 23.60 Funding and Investment Analysis: Distribution of Cumulative Number of Instances by Year, Pre 2013-2020
Table 23.61 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, Pre 2012-2019 (USD Million)
Table 23.62 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre 2013-2020
Table 23.63 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, Pre 2013-2020 (USD Million)
Table 23.64 Funding and Investment Analysis: Distribution of Amount Invested across Different Types of Products
Table 23.65 Most Active Players: Distribution by Number of Instances
Table 23.66 Funding and Investment Analysis: Distribution of Amount Invested across Different Types of Investors
Table 23.67 Most Active Investors: Distribution by Number of Instances
Table 23.68 Funding and Investment Analysis: Distribution by Geography
Table 23.69 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
Table 23.70 Other T-Cell Immunotherapies: Distribution by Phase of Development
Table 23.71 Other T-Cell Immunotherapies: Distribution by Target Therapeutic Area
Table 23.72 Other T-Cell Immunotherapies: Distribution by Type of Cells
Table 23.73 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Table 23.74 Overall T-Cell Immunotherapy Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 23.75 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2030 (USD Billion)
Table 23.76 T-Cell Immunotherapy Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Table 23.77 T-Cell Immunotherapy Market: Distribution by Target Antigens(s), 2025 and 2030 (USD Billion)
Table 23.78 T-Cell Immunotherapy Market: Distribution by Key Players, 2025 and 2030 (USD Billion)
Table 23.79 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 23.80 Overall CAR-T Cell Therapies Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 23.81 CAR-T Cell Therapies Market: Distribution by Target Indication(s) (USD Billion)
Table 23.82 CAR-T Cell Therapies Market: Distribution by Target Antigen(s) (USD Billion)
Table 23.83 CAR-T Cell Therapies Market: Distribution by Key Players (USD Billion)
Table 23.84 CAR-T Cell Therapies Market: Distribution by Geography (USD Billion)
Table 23.85 KYMRIAH® (Novartis): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.86 YESCARTA® (Gilead Sciences): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.87 Tecartus® / Brexucabtagene Autoleucel (Gilead Sciences): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.88 Idecabtagene Vicleucel / bb2121 (bluebird bio / Celgene): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.89 Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.90 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.91 MB-CART19.1 (Miltenyi Biotec): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.92 Descartes-11 (Cartesian Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.93 MB-102 (Mustang Bio): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.94 huCART19 / CTL119 (Novartis): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.95 CD19 CAR-T (Sinobioway Cell Therapy): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.96 AUTO1 (Autolus): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.97 AUTO3 (Autolus): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.98 AUTO4 (Autolus): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.99 GPC3 CAR-T (Shanghai GeneChem): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.100 BCMA CAR-T (The Beijing Pregene (ShenZhen) Biotechnology): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.101 CD19 CAR-T (The Beijing Pregene (ShenZhen) Biotechnology): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.102 CD19 CAR-T (Shanghai Bioray Laboratory): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.103 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.104 PCAR-019 (PersonGen BioTherapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.105 TBI-1501 (Takara Bio): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.106 IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.107 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.108 BinD19 (Shenzhen BinDeBio): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.109 CARCIK-CD19 (Formula Pharmaceuticals): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.110 EGFR CART (The Beijing Pregene Science and Technology): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.111 Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.112 PBCAR269A (Precision BioSciences): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.113 BCMA CAR-T (Chongqing Precision Biotech): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.114 CEA CAR-T cells (Chongqing Precision Biotech): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.115 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Sales Forecast Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.116 P-BCMA-101 (Poseida Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.117 CD19 CAR-T (iCarTAB BioMed): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.118 BPX-601 (Bellicum Pharmaceuticals): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.119 MUC1 CAR-T (PersonGen BioTherapeutics (Suzhou)): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.120 Overall TCR-based Therapies Market Forecast, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 23.121 TCR-Based Therapies Market: Distribution by Target Indication(s) (USD Billion)
Table 23.122 TCR-Based Therapies Market: Distribution by Target Antigen(s) (USD Billion)
Table 23.123 TCR-Based Therapies Market: Key Players (USD Billion)
Table 23.124 TCR-Based Therapies Market: Distribution by Geography (USD Billion)
Table 23.125 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.126 IMCgp100 (Immunocore): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.127 ADP-A2M4 (Adaptimmune Therapeutics): Sales Forecast Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.128 TBI-1301 (Takara Bio): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.129 ALT-801 (Altor Bioscience): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.130 JTCR016 (Juno Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.131 LioCyx (Lion TCR): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.132 YT-E001 (China Immunotech): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.133 MDG1011 (Medigene): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.134 TC-110 (TCR2 Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.135 LMBP2-specific TCR-T (TCR CURE Biopharma Technology): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.136 Overall TIL-based Therapies Market Forecast: Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 23.137 TIL-Based Therapies Market: Distribution by Target Indication(s) (USD Billion)
Table 23.138 TIL-Based Therapies Market: Key Players (USD Billion)
Table 23.139 TIL-Based Therapies Market: Distribution by Target Geography (USD Billion)
Table 23.140 TILs (Nantes University Hospital) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.141 TILs (The Netherlands Cancer Institute): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.142 Lifileucel (LN-144) (Iovance Biotherapeutics): Sales Forecast Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.143 LN-145 (Iovance Biotherapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.144 LTX-315 and TILs (Lytix Biopharma): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.145 IOV-2001 (Iovance Biotherapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.146 Allogeneic Donor Lymphocytes (Amgen): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.147 Donor Lymphocyte Infusion (Incyte): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.148 TILs (Bristol-Myers Squibb): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.149 UTIL-01 and CoTIL-01 (Immetacyte): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.150 TILs (Intima Bioscience): Sales Forecast Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)

List Of Company

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 5AM Ventures
  2. 6 Dimensions Capital
  3. AbbVie Ventures
  4. AbCheck
  5. AbClon
  6. Abingworth
  7. AbVitro
  8. Aditya Birla Capital
  9. ACEA Biosciences
  10. Acorn Pacific Ventures
  11. Adage Capital Management
  12. Adaptimmune Therapeutics    
  13. Adicet Bio
  14. Adimab
  15. Aeon Therapeutics
  16. AffyImmune Therapeutics
  17. AFG private Equity
  18. Agent Capital
  19. AgenTus Therapeutics
  20. Agreen Biotech 
  21. Aisling Capital 
  22. Aju IB
  23. AJU IB INVESTMENT
  24. AK (Suzhou) Biomedical
  25. Alexandria Venture Investments
  26. Allife Medical Science and Technology
  27. Allogene Therapeutics
  28. Alpine Immune Sciences
  29. Alta Partners
  30. Altor Bioscience
  31. Alumni Ventures Group (AVG)
  32. Amgen
  33. Amgen Ventures
  34. Andera Partners
  35. Andreessen Horowitz
  36. ANTAGENE
  37. Aquilo Capital Management 
  38. Arbele
  39. Arcellx
  40. ARCH Venture Partners
  41. Arix Bioscience
  42. ArrowMark Partners
  43. A*STAR Research
  44. Astellas Pharma
  45. Astellas Venture Management
  46. Asymptote 
  47. AT Impf
  48. Atara Biotherapeutics
  49. Atlas Venture
  50. Atossa Therapeutics
  51. Atreca 
  52. Aurora Biopharma
  53. Autolus
  54. Avacta
  55. Avalon GloboCare
  56. Avoro Capital Advisors
  57. AVIC International Holding
  58. Baader Bank
  59. Baillie Gifford
  60. BankInvest Biomedical Venture
  61. Baxalta
  62. Baxalta Ventures
  63. Baxter Ventures
  64. Baylor College of Medicine
  65. Be The Match BioTherapies
  66. Beam Therapeutics
  67. Beijing Biohealthcare Biotechnology
  68. Beijing Doing Biomedical Technology
  69. Beijing Immunochina Medical Science & Technology 
  70. Beijing Mabworks Biotech
  71. Beijing Mario Biotech
  72. Beijing Sanwater Biological Technology
  73. Belgian Public Health Insurer
  74. Bellco Capital
  75. Bellicum Pharmaceuticals
  76. Bessemer Venture Partners
  77. Bezos Expeditions
  78. Bill & Melinda Gates Foundation 
  79. BioAtla
  80. Bioceltech Therapeutics
  81. Bio-Gene Technology
  82. Biomedical Catalyst 
  83. BioNTech
  84. Biosceptre
  85. bluebird bio
  86. BNH Investment
  87. Boehringer Ingelheim 
  88. Boxer Capital 
  89. Boya Jiyin
  90. Bpifrance
  91. Brace Pharma Capital
  92. BrightEdge 
  93. Bristol Myers Squibb
  94. Broadfin Capital
  95. BVCF Management
  96. Cabaret Biotech
  97. Caladrius Biosciences
  98. California Institute for Regenerative Medicine (CIRM) 
  99.     Canaan Partners
  100. Cancer Prevention and Research Institute of Texas 
  101. Captain T Cell
  102. Caribou Biosciences
  103. Carina Biotech
  104. CARsgen Therapeutics
  105. CAR-T (Shanghai) Biotechnology
  106. Cartesian Therapeutics
  107. Cartherics
  108. Casdin Capital
  109. Casebia Therapeutics
  110. Celgene
  111. Cell and Gene Therapy Catapult
  112. Cell Design Labs
  113. Cellectis
  114. CELLforCURE
  115. Cellular Biomedicine Group 
  116. Cellular Therapeutics
  117. Celyad 
  118. Chengdu Miaoji Medical Technology
  119. Children’s Hospital of Philadelphia
  120. China (Nanjing) Cell Valley 
  121. China Immunotech (Beijing) Biotechnology
  122. China Regenerative Medicine International (CRMI)
  123. Chongqing Precision Biotech
  124. Clough Capital Partners
  125. Cognate BioServices
  126. Cormorant Asset Management
  127. Cowen Healthcare Investments
  128. CRISPR Therapeutics
  129. Cryoport
  130. CTI Clinical Trial and Consulting Services
  131. CTM CRC
  132. Curative Ventures
  133. CureSearch
  134. CytoLumina Technologies
  135. CytoMed Therapeutics
  136. Cytovant Sciences
  137. Deerfield Management
  138. Delenex Therapeutics  
  139. dievini Hopp Biotech
  140. Direct Selling Association of Malaysia (DSAM)
  141. Ditch Plains Capital Management
  142. DS Asset Management
  143. Duke Management Company
  144. EcoR1 Capital
  145. EDBI
  146. Editas Medicine 
  147. Edmond de Rothschild Venture Capital
  148. Efung Capital
  149. Eli Lilly
  150. Endocyte
  151. The Energy and Resources Institute
  152. Eureka Therapeutics
  153. European Commission
  154. European Innovation Council (EIC) 
  155. European Investment Bank
  156. Eutilex
  157. EXUMA Biotech
  158. F1 BioVentures
  159. F2 Ventures
  160. Fate Therapeutics
  161. FetoLumina Technologies 
  162. Federal Ministry of Education and Research (BMBF)
  163. Fidelity Biosciences
  164. Fidelity Management and Research
  165. Finnish Funding Agency for Technology and Innovation
  166. Five Prime Therapeutics
  167. Five Rings Capital
  168. Flagship Pioneering
  169. Flagship Ventures
  170. Fondazione Matilde Tettamanti Menotti De Marchi Onlus
  171. Foresite Capital
  172. Forevertek Biotechnology
  173. Formula Pharmaceuticals
  174. Fosun Pharmaceutical
  175. Fotress Biotech
  176. F-Prime
  177. Franklin Templeton Investments
  178. Friedreich’s Ataxia Research Alliance (FARA)
  179. Fundamenta Therapeutics
  180. G.N. Tech Venture
  181. Gadeta
  182. GC LabCell
  183. GC Pharma
  184. GE Global Research
  185. GE Healthcare Life Sciences 
  186. Genentech
  187. Genmab
  188. Genus Oncology
  189. GigaGen
  190. Gilead Sciences
  191. GlaxoSmithKline
  192. Glycostem 
  193. GlyTherix
  194. Google Ventures
  195. GP Capital
  196. Gracell Biotechnologies
  197. Grower Venture Capital
  198. Guangdong Chongye Holdings
  199. Guangdong Xiangxue Precision Medical Technology
  200. Guangdong Zhaotai InVivo Biomedicine
  201. Guangzhou Anjie Biomedical Technology
  202. Guangzhou FineImmune Biotechnology
  203. Guangzhou Yi yang Biological Technology
  204. GV
  205. Haitong International Securities Group
  206. Hebei Senlang Biotechnology
  207. Helix BioPharma
  208. Henan Hualong Biotechnology 
  209. Hengzhen Biotechnology
  210. Hillhouse Capital Group
  211. Hopp Biotech holding
  212. Horizon Discovery
  213. Horizon Technology Finance
  214. Hrain Biotechnology
  215. HuaDao (Shanghai) Biomedical
  216. Hudson Bay Capital Management 
  217. Hunan Yongren Medical Innovation 
  218. Hunan Zhaotai Yongren Biotech
  219. Hunan Zhaotai Yongren Medical Innovation
  220. iCAR Bio Therapeutics 
  221. iCarTAB BioMed
  222. iCell Gene Therapeutics
  223. Icell Kealex Therapeutics
  224. ICON
  225. Immatics
  226. Immetacyte
  227. Immune Therapeutics
  228. Immunocore
  229. Imperial Innovations
  230. Innovate UK
  231. Innovative Cellular Therapeutics
  232. Intellia Therapeutics
  233. Intima Bioscience
  234. Invectys
  235. Invesco Perpetual
  236. Investing Women
  237. Iovance Biotherapeutics
  238. IRICoR
  239. Janssen
  240. Janus Capital Group
  241. Janus Henderson Investors
  242. Japan Science and Technology Agency (JST)
  243. Jebsen Capital
  244. Jianxin Capital
  245. JIC GenesisFountain Healthcare Ventures
  246. Jichi Medical University
  247. Johnson & Johnson Innovation
  248. Jolly Innovation Ventures
  249. Junchenda Capital
  250. Juno Therapeutics
  251. Juventas Cell Therapy
  252. JVC Investment Partners
  253. JW Biotechnology
  254. JW Therapeutics
  255. KAEDI
  256. Kaitai Capital
  257. Karolinska Institute
  258. Karst Peak Capital
  259. Kecellitics Biotech
  260. Key Biologics
  261. Khosla Ventures
  262. King Star Capital
  263. Kington Capital
  264. Kite Pharma
  265. Kleiner Perkins
  266. Kolon Investment
  267. Kuur Therapeutics
  268. KSQ Therapeutics
  269. KTB Ventures
  270. Laurion Capital Management
  271. Legend Biotech
  272. Legend Capital 
  273. Leiden University Medical Center
  274. Leucid Bio
  275. Level One Partners
  276. LG Technology Ventures
  277. LH Ventures
  278. Life Technologies
  279. Lifeline Ventures
  280. Lightstone Ventures
  281. Lilly Asia Ventures
  282. Liminatus Pharma
  283. Lion TCR 
  284. Living Pharma
  285. Longitude Capital
  286. Lonza
  287. Lonza Biologics
  288. Loyal Valley Capital
  289. Lucion Group
  290. LUMICKS
  291. Lupus Ventures
  292. Lyell Immunopharma
  293. Lytix Biopharma
  294. MabQuest 
  295. MabVax Therapeutics Holdings
  296. Malin
  297. Marino Biotechnology
  298. Marker Therapeutics
  299. MaSTherCell
  300. Matrix Capital Management
  301. MaxCyte
  302. Maxim Group
  303. MD Anderson Cancer Center 
  304. Medicxi Ventures
  305. Medigene 
  306. MedImmune
  307. Medisix Therapeutics 
  308. Medivate Partners
  309. Memorial Sloan Kettering Cancer Center
  310. Merck
  311. Merck Serono
  312. Merlin Nexus
  313. Mesoblast
  314. Miller Value Partners
  315. Miltenyi Biotec
  316. Minerva Biotechnologies
  317. MingJu Therapeutics
  318. Mirae Asset Capital
  319. Mirae Asset Venture Investment
  320. Mirae Asset Financial Group
  321. Mission Bay Capital
  322. MIT Zuid 
  323. MolMed
  324. MPM Capital
  325. MSD Partners
  326. Mustang Bio
  327. NantKwest
  328. NantWorks
  329. National Cancer Institute
  330. National Institute of Allergy and Infectious Diseases 
  331. National Institutes of Health
  332. NCL Innovation
  333. New Enterprise Associates
  334. New Leaf Venture Partners
  335. Nextech Invest
  336. NIH Small Business Innovation Research (SBIR) 
  337. NIPRO
  338. Nohla Therapeutics
  339. Noile-Immune Biotech
  340. Norwegian Research Council (NRC) 
  341. Notch Therapeutics
  342. Novartis
  343. Novartis Institutes for BioMedical Research (NIBR)
  344. Novo Nordisk
  345. Novo Holdings
  346. NSR Financial
  347. Oaktree Capital Management
  348. Obsidian Therapeutics
  349. Oberland Capital Healthcare
  350. OCV Partners
  351. ODYSSEE Venture
  352. Omega Fund 
  353. Oncodesign Biotechnology
  354. Oncora Medical
  355. OncoTracker
  356. Oncyte
  357. ONO pharmaceutical
  358. Opus Bio 
  359. OrbiMed Advisors
  360. Osage University Partners
  361. Oxford Biomedical Research
  362. Oxford MEStar 
  363. PACT Pharma
  364. Panacea Venture
  365. Parker Institute for Cancer Immunotherapy
  366. Partners Innovation Management
  367. Penn Medicine
  368. Pentwater Capital Management
  369. PeproMene Bio
  370. Perceptive Advisors
  371. Perceptive Bioscience Investments
  372. PersonGen BioTherapeutics (Suzhou)
  373. Perspective Advisors
  374. Pfenex
  375. Pfizer
  376. PharmaCell
  377. Phio Pharmaceuticals
  378. Ping An Ventures
  379. Pinze Lifetechnology
  380. Pitango Venture Capital
  381. Platinum Asset Management
  382. Polaris Partners
  383. PolyBioCept
  384. Pontifax
  385. Pontifax AgTech
  386. POSCO Capital
  387. Poseida Therapeutics
  388. Precigen
  389. Precision BioSciences
  390. Progenitor Cell Therapy
  391. ProMAB Biotechnologies
  392. Prometheus Laboratories
  393. Protheragen
  394. PureTech Health
  395. Qian Hai Wan Hui Equity Investment Fund Management (Shenzhen)
  396. Quan Capital
  397. Quogue Capital
  398. QVT Financial
  399. RA Capital Management
  400. Redmile Group
  401. RedoxTherapies
  402. Regeneron 
  403. Remeditex Ventures
  404. resTORbio
  405. Ridgeback Capital Management
  406. Roche
  407. Rock Spring Capital
  408. Rockland Immunochemicals
  409. RTW Investments
  410. S.R. One
  411. Sabby Management
  412. Samsara BioCapital
  413. Sangamo Therapeutics
  414. Sanofi Ventures
  415. Schonfeld Strategic Advisors
  416. Scotia Biologics
  417. Scottish Enterprise
  418. Scottish Investment Bank (SIB)
  419. Seattle Genetics
  420. Sectoral Asset management
  421. Sensei Biotherapeutics
  422. Sequoia Capital China
  423. Servier
  424. Shandong Boyuan Pharmaceutical
  425. Shanghai Biomed-Union Biotechnology
  426. Shanghai Bioray Laboratory
  427. Shanghai Longyao Biotechnology 
  428. Shanghai PerHum Therapeutics
  429. Shanghai Pudong Innovation Technology Investment
  430. Shanghai Sinobioway Sunterra Biotech
  431. Shanghai Unicar-Therapy Bio medicine Technology
  432. Sheba Medical Center 
  433. Shenzen Venture Capital
  434. Shenzhen BinDeBio
  435. Sherpa Venture Capital
  436. Shionogi
  437. Shiyu Capital
  438. Sinobioway Cell Therapy
  439. Sinobioway Group
  440. Sino-Singapore Chongqing Connectivity Private Equity Fund Management
  441. Sirona Capital
  442. Smilegate Investment
  443. SNU Bio Angel
  444. Sorrento Therapeutics
  445. SpringWorks Therapeutics
  446. Square One Bank
  447. SR One
  448. Stage Cell Therapeutics 
  449. Stanford University
  450. Statcom 
  451. Steam Athena Capital
  452. Stratophase 
  453. SunTerra Capital
  454. Super-T Cell Cancer Company
  455. Suzhou Oriza Holdings
  456. Symvivo
  457. Syncona
  458. SyndicateRoom
  459. Syno Capital
  460. Synthace 
  461. Syracuse Biopharma
  462. T. Rowe Price Group
  463. Tactiva Therapeutics
  464. Taiho Ventures and Wu Capital
  465. Takara Bio
  466. Takeda Pharmaceutical
  467. Takeda Ventures
  468. Targazyme
  469. Tavistock Group
  470. TC BioPharm
  471. T-Cell Factory 
  472. TCR2 Therapeutics
  473. TCRCure Biopharma
  474. Technology Strategy Board
  475. Tekla Capital Management
  476. Temasek Holdings
  477. Teneobio
  478. Tessa Therapeutics
  479. The Beijing Pregene Science and Technology
  480. The Invus Group
  481. The Pregene (ShenZhen) Biotechnology
  482. The University of Texas Health Science Center
  483. Thermo Fisher Scientific
  484. Third Rock Ventures
  485. Tianjin Mycure Medical Technology
  486. TILT Biotherapeutics
  487. Timmune Biotech
  488. Tmunity Therapeutics
  489. TNK Therapeutics
  490. Touchstone Innovations
  491. TPG
  492. TrakCel
  493. Transgene
  494. Transposagen Biopharmaceuticals
  495. Trout Capital 
  496. Tscan Therapeutics
  497. Two River
  498. TxCell 
  499. Union Stem Cell & Gene Engineering
  500. Universal Cells
  501. University of California
  502. University of Montreal
  503. University of Oxford
  504. University of Pennsylvania
  505. Unum Therapeutics
  506. Utrecht Holdings
  507. UWELL Biopharma
  508. V Foundation
  509. venBio
  510. Venrock
  511. Versant Ventures
  512. Vi Ventures
  513. Vida Ventures
  514. Viking Global Investors
  515. ViroMed Laboratories
  516. Vitruvian Networks
  517. Vivo Capital
  518. Vor Biopharma
  519. Weill Cornell Medical College
  520. Wellcome Trust 
  521. Wellington Management
  522. Wellington Partners
  523. Wellington Zhaotai Therapies
  524. Westlake Ventures
  525. Westlake Village BioPartners
  526. WH Partnership
  527. White Rock Capital Management
  528. WindMIL Therapeutics
  529. Woodford Investment Management
  530. Wugen
  531. Wuhan Bio-Raid Biotechnology
  532. Wuhan Dangdai Science and Technology Industries Group
  533. Wuhan Sian Medical Technology
  534. WuXi AppTec
  535. Xi'An Yufan Biotechnology
  536. Xiangxue Life Sciences
  537. Xiangxue Pharmaceutical
  538. Xinyi Capital
  539. Yake Biotechnology
  540. Yipu Capital
  541. YuanMing Capital
  542. Yuanyi Biotechnology
  543. Zelluna Immunotherapy 
  544. Zhejiang HUACHENG Holdings Group
  545. Zhejiang Huahai Pharmaceutical 
  546. Ziopharm Oncology

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com